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CHAPTER 1: Introduction
1.1 Methamphetamine abuse and its consequences:
Addiction and drug abuse are currently major problems in the United States. About
100,000 Americans die every year as victims of illicit drug abuse and millions of others suffer
from social and economic disruption. Illicit drug use accounts for about $181 billion per year
economically. As per the NIDA definition, “Addiction is defined as a chronic, relapsing brain
disease that is characterized by compulsive drug seeking and use, despite harmful
consequences”(www.drugabuse.gov).

1.1.1 Properties of Methamphetamine:
Methamphetamine (METH) is a derivative of amphetamine. Both drugs are popular
psychostimulants used for their euphoric effect and for recreation. Amphetamine is a
methaylated phenylethylamine whereas METH is a double methylated phenylethylamine. Both
drugs are toxic (Figure 1.1). However, METH is more potent than amphetamine in the central
ervous

system

(CNS)

and

its

effects

manifest

at

(http://amphetamines.com/amphetamines-vs-methamphetamines).

a

much

faster

rate
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Amphetamine

Methamphetamine

Figure 1.1 Chemical structure of amphetamine (left) and METH (right).
METH is a substituted amphetamine (pubchem.ncbi.nlm.nih.gov).

METH crosses the placenta and is secreted into breast milk (Bartu, Dusci et al. 2009).
METH is mainly metabolized in the liver with several metabolites found in the urine.
Metabolism occurs by aromatic hydroxylation, N-dealkylation and deamination. METH has
several metabolites (Figure 1.2). Amphetamine, which is an active metabolite of METH, is also
neurotoxic (Torre, Yubero-Lahoz et al. 2012). The half-life of METH is different in humans and
rats. In humans, the half-life is about 10-12 h (depending on the route of administration) (Cook,
Jeffcoat et al. 1992, Cook, Jeffcoat et al. 1993) as compared to about 1 h in rats (Melega,
Williams et al. 1995). Since the half-life of METH in rats is much shorter compared to humans,
binge regimen is used to keep the plasma levels of the drug comparable to that in humans.
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Figure 1.2 METH and its metabolites. METH is mainly metabolized in the liver
and converted to the active metabolite amphetamine by N-dealkylation. Other
metabolites of METH include 4-hydroxymethamphetamine (by aromatic
hydroxylation) and deamination products of amphetamine such as cathinone,
hippuric acid, benzoic acid and phenylacetone (DrugBank, University of
Alberta).

METH causes a rapid rush of pleasure and euphoria due to release of dopamine (DA) in
the nucleus accumbens by acting on DA transporters (Sulzer, Chen et al. 1995, Rothman and
Baumann 2003). Other immediate effects are increased wakefulness, increased physical
activity, rapid heart rate, elevation of blood pressure, suppression of appetite and increased
body temperature. High doses of METH can cause insomnia, psychosis, paranoia, seizures and
stroke (Winslow, Voorhees et al. 2007) (www.drugabuse.gov).

1.1.2 History of METH use:
METH has been used as early as the World War I and abuse of the drug reached its peak
in 1960s. In the 1930s, amphetamines were freely available as over the counter inhalers and
tablets for a variety of conditions such as asthma, narcolepsy and obesity. The non-prescription
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amphetamine inhaler Benzedrine became very popular for treating asthma and congestion.
Other off label uses for METH included schizophrenia, morphine addiction, alcoholism,
migraine, head injuries, hypotension and many others. During the World War II, soldiers used it
extensively as it increased wakefulness, suppressed fatigue and appetite. For the same reason,
it was also used by athletes and by students to increase attention (Anglin, Burke et al. 2000,
Shukla, Crump et al. 2012). Following this, the Drug Abuse Control Amendments of 1965 and
the Comprehensive Drug Abuse Prevention and Control Act of 1970 restricted the use of
amphetamines, classifying them as Schedule II drugs (Vearrier, Greenberg et al. 2012).
A schedule II drug, today METH is available only through prescription and cannot be
refilled. Its medical use is confined to conditions like Attention Deficit Hyperactivity Disorder
(ADHD), narcolepsy and obesity (Lambert, Windmiller et al. 1976, Bramble 2000). Illegal METH
has different street names such as crystal, chalk, crank, speed, batu, crystal, yaba. It is
administered by snorting, smoking, by injection and sometimes orally. Increased monoamine
transmission mediated by METH is responsible for most of its abuse potential due to effects like
euphoria and increased wakefulness (Vearrier, Greenberg et al. 2012). However, chronic use of
METH is associated with neurotoxicity.

1.1.3 Epidemiology of METH abuse:
Amphetamines are the second most prevalent illicit drugs in the world after cannabis
(Vearrier, Greenberg et al. 2012). According to NIDA, about 13 million people have used METH
at least once in their lifetime. As compared to previous years, the use of METH in the United
States has declined after 2000. However, it is still abused by a high number of people. For
instance, METH use has remained steady, from 530,000 current users in 2007 to 440,000 in
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2012

(http://www.drugabuse.gov/publications/drugfacts/nationwide-trends).

Furthermore,

METH abuse might be on a rise again as METH-related visits to United States emergency rooms
(ERs) jumped from 67,954 in 2007 to 102,961 in 2011. Out of the total people receiving
treatment for METH abuse, 6.7% were pregnant women in 2009 (SAMHSA 2011, TEDS). Also,
among pregnant women aged 15-44, the average rate of illicit drug use in 2011-2012 was found
to be 5.9% (SAMHSA (2012).
In addition, the use of amphetamines seems to have increased among 12th graders and
stopped declining among 8th and 10th graders from the year 2009. It has been hypothesized that
METH is abused as an aid to their studies (Monitoring the Future Study 2013) (Figure 1.3). Along
with this, METH abuse is getting increasingly popular in other parts of the world, especially
Asian countries (Griffiths, Mravcik et al. 2008, McKetin, Kozel et al. 2008).

Figure 1.3 Use of amphetamines by college students and high school
students. Recent increase in the use of amphetamines by college students
has been observed (Monitoring the Future, Institute for Social Research,
University of Michigan) (Johnston, O’Malley et al. 2014).
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1.1.4 Clinical signs and symptoms of chronic METH abuse:
When taken at high doses, METH causes selective degeneration of dopaminergic
(DAergic) and serotonergic (5HTergic) nerve terminals in the brain in both experimental animals
and humans (Wilson, Kalasinsky et al. 1996, Quinton and Yamamoto 2006, Krasnova and Cadet
2009). High-dose METH causes a variety of negative behavioral changes in addition to
compulsive drug seeking and drug taking, such as cognitive impairments, anxiety, violent
behavior and psychosis (Salo, Nordahl et al. 2009, Ares-Santos, Granado et al. 2013). Long-term
use of METH causes DA depletion in the striatum along with cognitive impairments and other
problems including “METH mouth” (tooth decay) (Hart, Marvin et al. 2012). Neuropsychological
effects like decrease in decision making ability (Rogers, Everitt et al. 1999), confusion,
hallucination, decreased memory (Braren, D et al. 2014) and psychosis (Flaum and Schultz
1996) also result from chronic use of METH. Long term effects of METH use include tolerance to
the effect of METH which causes METH users to escalate their dose to produce the same effects
(Gygi, Gygi et al. 1996).
Along with adults, METH has fatal effects on children exposed to the drug in the uterus.
METH use by pregnant women has become a major concern due to long term risks to the
exposed fetus. Clinical studies in humans have found that exposure to METH during brain
development can cause neurobehavioral abnormalities such as aggressive behavior, learning
problems and poor social adaptation later in life (LaGasse, Derauf et al. 2012, Diaz, Smith et al.
2014). METH produces a variety of effects on the body. Some of the major effects are:
1.

Addiction
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2.

Cognitive impairments: Low doses of METH improves cognitive performance and

memory but long term use of METH causes cognitive impairment, loss of memory and attention
(Nordahl, Salo et al. 2003).
3.

Violent/aggressive behavior (McKetin, Lubman et al. 2014).

4.

Psychotic symptoms: METH use is associated with seizures. Other effects include

hallucinations, delusions and paranoia (Zweben, Cohen et al. 2004).
5.

Cardiovascular: hypertension and tachycardia (Newton, Garza et al. 2005).

6.

Immune system: METH users are more prone to engaging in risky sex as

compared to non-METH users. The chance of getting Human Immunodeficiency virus (HIV)
increases by engaging in unsafe sex. Heterosexual men abusing METH are more susceptible to
infection by HIV. Also, since METH administration by injection is fairly common, the risk of
getting HIV through contaminated needles or sharing needles is fairly high (Molitor, Truax et al.
1998, Morb 2006).
7.

METH mouth: tooth decay

8.

Prenatal exposure: METH abuse by pregnant women leads to adverse effects in

infants. Effects like impaired growth of fetus, premature delivery, and low body weight with
smaller head circumference of the infant as well as neonatal hepatitis have been observed (Oro
and Dixon 1987, Little, Snell et al. 1988, Dahshan 2009).
9.

Suicidal tendencies (Richards, Bretz et al. 1999).

10.

Risk of developing Parkinson’s disease: METH neurotoxicity and Parkinson’s

disease have similar profiles of brain damage, and there are studies showing correlation
between the two. METH users have been found to have double the risk of developing
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Parkinson’s disease than non-METH users. A population study showed that METH users have
increased incidence of Parkinson’s disease later in life (Callaghan, Cunningham et al. 2010,
Callaghan, Cunningham et al. 2012).

1.2 Neurotoxicity of METH
The clinical symptoms of METH are manifestations of its neurotoxicity at the molecular
level. The Interagency Committee on Neurotoxicology defined neurotoxicity as:
“Permanent and reversible effects on the structure or function of the nervous system; a
toxic effect of the drug that causes one or more of the following:


Loss

of

neuronal

components (e.g. synthesizing enzymes, receptors,

transporters, neurotransmitters, nerve cells and terminals)


Histological signs of neuronal damage (silver staining, gliosis, swollen axons)



A loss of the entire neuron and components therein



A persistent behavioral abnormality associated with the drug.” (From Dr.

Moszczynska’s presentation).
METH toxicity is manifested by one or more of the above conditions. Binge METH (4x5
mg/kg, 4x7.5 mg/kg and 4x10 mg/kg, every 2 h, i.p.) causes significant reduction in DA and 5HT
content in the striatum in rats, 7 days following the drug treatment (Matuszewich and
Yamamoto 2004, Tata, Raudensky et al. 2007). In mice, METH affects only the DAergic system
with majority of previous studies showing a lack of METH-induced toxicity in the 5HTergic
system (Jonsson and Nwanze 1982, Anderson and Itzhak 2006). Studies in human chronic METH
users showed decreases in DA, TH, DAT and 5HTergic transporter (SERT) levels in the striatum,
without affecting the cell bodies. The levels of vesicular monoamine transporter (VMAT2) and
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dopa decarboxylase (DDC) remained unchanged, suggesting lack of permanent damage to the
nerve terminals (Wilson, Kalasinsky et al. 1996, Chang, Alicata et al. 2007). However, a more
recent study found that following oral dose of amphetamine, there is a 5% reduction in VMAT2
binding in the striatum as observed by positron emission tomography (PET) scan (Boileau,
Houle et al. 2010). In non-human primates (monkeys), deficiencies in DAergic system are
observed as early as 1 week after METH as seen with PET scan and they are persistent. The
decreases in DAT, TH and VMAT2 are still observed in striatum one month after METH (Harvey,
Lacan et al. 2000). Rats have a toxicity profile that is similar to humans. Although many studies
on binge METH effect on DA and its metabolites have looked at 7 days following the drug
treatment (Matuszewich and Yamamoto 2004, Tata, Raudensky et al. 2007), decreases in DA,
3,4-dihydroxyphenylacetic acid (DOPAC), 5-HT and 5-hydroxyindoleacetic acid (5-HIAA)
following binge METH (6x5 mg/kg, every 1 h, i.p.) have been observed as early as 24 h after
METH (Hodges, Ladenheim et al. 2011). The time course of development of METH toxicity as
well as recovery from it varies between species. Mice show astrogliosis as early as 24 h after
METH (O’Callaghan and Miller 1994). In rats, microglia activation in the striatum is observed 5
days after and astrocytosis is observed 3 days following METH (Guilarte, Nihei et al. 2003).
When single high METH dose (40 mg/kg) is given to rats, significant reduction in TH levels and
increased levels of the astrogliosis marker GFAP (glial fibrillary acidic protein) are observed in
the striatum as early as at 12 h and 6 h, respectively. The DA depletion with this METH dose
was found to occur also at 12 h after the injection of the drug (Cappon, Pu et al. 2000). Granular
degeneration of nerve terminals in rat striatum, as detected by silver staining, has been
observed at 4 days following high dose binge METH (3x50 mg/kg, every 8 h). No degeneration
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was observed in other brain regions such as SNPc and hypothalamus (Ricaurte, Guillery et al.
1982).
As mentioned before, most of the toxicity studies have shown that the damage caused
by METH is reversible with time. However, the recovery may or may not be complete and the
duration for recovery is different based on the dose of METH and severity of the damage. Also,
as mentioned before, there are interspecies differences in the time when recovery takes place.
Only one study in rats so far has showed recovery of all the parameters of the DAergic system,
12 months after binge regimen of METH. This study used a single non-toxic dose of 5 mg/kg
METH (Manning and Cass 1999). However, studies using higher dose of METH (4x12.5 mg/kg,
every 2 h), showed reduction in DA and DOPAC 237 days after the treatment (Friedman,
Castañeda et al. 1998). In humans, increased availability of DAT (recovery) is observed after 14
months of abstinence from METH (Volkow, Chang et al. 2001). In monkeys, DAergic markers
recover to normal levels after 1.5 years. However, no axonal regeneration has been reported in
any of the studies which indicates lack of complete recovery of nerve terminals (Melega,
Raleigh et al. 1997, Harvey, Lacan et al. 2000).

1.2.1 Dopaminergic system:
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Figure 1.4: Dopamine (DA) and Serotonin (5HT) Pathways. These are two
main systems damaged by METH in most species. The nigrostriatal DA
pathway, which comprises of projections from the nerve cell bodies in
the substantia nigra pars compacta (SNPc) to the striatum, is the most
affected by high-dose METH. Our study focuses on the toxicity of METH
to DAergic terminals in the striatum (www.drugabuse.gov;
NIDA)(Cooper, Bloom et al. 2003).

The DAergic system has four different pathways;
(1)

Mesolimbic pathway

(2)

Mesocortical pathway

(3)

Nigrostriatal pathway

(4)

Tuberoinfundibular pathway (Cooper, Bloom et al. 2003).

Of major interest in METH neurotoxicity is the nigrostriatal pathway because the
striatum is the brain area most severely affected by METH. The nigrostriatal pathway comprises
of the projections from cell bodies in the SNPc to the striatum (also referred to as the dorsal
striatum) (Figure 1.4). DAergic projections from the ventral tegmental area (VTA), project to the
nucleus accumbens (also referred to as the ventral striatum or limbic striatum) forming the
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mesolimbic DA pathway and to the prefrontal cortex forming the mesocortical DA pathway. The
tuberoinfundibular pathway connects the hypothalamus with the pituitary gland (Cooper,
Bloom et al. 2003). The striatum is the most affected by METH due to its high content of DA.
Striatal function is involved in motor coordination and cognitive processes such as working
memory (Rolls 1994).

1.3 Dopaminergic terminal
1.3.1 Dopaminergic terminal structure and function:
The striatum contains abundant DAergic nerve terminals as compared to other DAcontaining regions where axons terminate. As aforementioned, these terminals are the
projections of DAergic cell bodies in the SNPc. As seen in the Figure 1.5, the DAergic nerve
terminal is structurally similar to other nerve terminals. The nerve terminal can be physically
divided into 2 main parts: cytoplasm and the nerve terminal membrane.
Cytoplasm: The cytoplasm of the nerve terminal contains mitochondria and the
endoplasmic reticulum (ER). DA storing vesicles as well as vesicles storing other neuronal
components are axonally transported to the cytosol from the cell bodies. These vesicles stay in
the cytoplasm till being docked at the membrane for exocytosis. The VMAT2 is present on the
surface of these synaptic vesicles. The VMAT2 is a proton pump that packages DA into vesicles.
There are 3 pools of synaptic vesicles in the presynaptic terminal: (1) reserve pool which is away
from the active zone (2) proximal recycling pool that is closer to the active zone (3) the
releasable pool of synaptic vesicles that are docked and ready for exocytosis. Proteins alpha-
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tubulin, beta-actin and bassoon are present in abundance in the cytosol (Volknandt and Karas
2012).
Membrane: The membrane of the nerve terminal is very dynamic and contains a
number of proteins for a variety of functions. Most common proteins observed in the plasma
membrane are transporters and channels (Na+/K+ ATPase; VDACs (voltage dependent anion
channel)), cell adhesion molecules, signaling mediators. Apart from this, the presynaptic active
zone contains a large number of exocytotic proteins (Volknandt and Karas 2012). Five main
proteins are present in the active zone: RIM, Munc13, RIM-BP, α-liprin and ELKS. These five
proteins assemble in one protein complex and mediate the docking of vesicles and recruitment
of calcium channels. Piccollo and bassoon make the framework of the active zone guiding the
movement of vesicles to the membrane. Filamentous proteins like cell division and control
related protein-1 (CDCrel-1) are also present attached to the plasma membrane as well as the
vesicles. Moreover, calcium channels and presynaptic neurotransmitter receptor (D2 receptors)
are found on the membrane of the nerve terminal (Sudhof 2004). DAT present on the
membrane of the terminal plays a very crucial role to reuptake DA from the synapse once it has
been released by exocytosis.
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Figure 1.5: Dopaminergic (DAergic) nerve terminal. DA packaged in vesicles is
transported axonally from the cell body to the nerve terminal. At the terminal,
DA is released from the vesicles by exocytosis. Once released in the synapse, DA
reuptake occurs via dopamine transporter (DAT) into the cytoplasm of the nerve
terminal. Free DA in the cytosol is then packaged into recycled vesicles by the
vesicular monoamine transporter 2 (VMAT2) residing in their membrane
(Cooper, Bloom et al. 2003).

1.3.2 Dopamine synthesis, storage, uptake, release and recycling:
DA is synthesized in the DAergic cell bodies as well as in DAergic terminals. Like other
catecholamines, it is synthesized from phenylalanine by a series of steps. Tyrosine hydroxylase
(TH) is the rate limiting enzyme in the synthesis of DA (Daubner, Lea et al. 2011). Once
synthesized in cell bodies, DA is packaged into synaptic vesicles and transported down to the
striatum (nerve terminals) by axonal transport. DA is also synthesized locally (Demarest and
Moore 1979). However, it is important that DA be stored inside the synaptic vesicles. At the pH
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of cytosol (pH 7.4, normal physiological pH), DA autooxidizes and causes oxidative damage to
the terminal (LaVoie and Hastings 1999). The pH inside the storage vesicles is acidic (between 55.7) which prevents autooxidation (Pothos, E Mosharov et al. 2002, Markov, Mosharov et al.
2008). Action potential leads to opening of calcium channels, which leads to docking and fusion
of the DA storage vesicles at the membrane of the nerve terminal for exocytosis. Docking of
vesicles occurs by formation of the 7S complex. The 7S complex is the protein complex formed
by the interaction between vesicle proteins v-SNARE and synapptotagmin along with
membrane proteins SNAP-25 and syntaxin (Scheller 1995). The post-synaptic effect of released
DA is terminated by reuptake or negative feedback mechanism. The released DA acts on D2
autoreceptor and negatively regulates its own exocytotic release. Following exocytosis and
post-synaptic action, DA reuptake into the nerve terminal occurs via DAT. Once inside the
terminal, the reloading of vesicles with DA occurs after the recycling of vesicles following
exocytosis. The vesicles are refilled with DA in one of the 3 ways: (1) vesicles are refilled with
DA without undocking (these vesicles constitute the readily releasable pool of DA) (2) the
vesicles undock and are refilled with DA (3) the vesicles undock, undergo clathrin mediated
endocytosis and are refilled with DA after fusion with endosomes (Sudhof 2004). Apart from
vesicle mediated exocytosis, somatodendritic release of DA occurs in brain regions other than
striatum (SNPc and VTA). Most of the neurotransmitters in the brain have point-to-point
synaptic contacts for signaling. However, DA signaling varies in this regard. Since most of the DA
receptors are extrasynaptic, a ‘spillover’ of DA from the synapse followed by diffusion into the
extrasynaptic space is commonly observed. This is known as volume transmission. As the
diffusion rate of DA is much faster than the reuptake rate, DAT cannot prevent the
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extrasynaptic spillover of DA. However, DAT does regulate the DA concentration in space and
time and also affects the active lifespan of DA. Thus, DAT plays an important role in regulating
the radius of DA effect (Cragg and Rice 2004, Rice, Patel et al. 2011).

1.4 Mechanisms of METH Neurotoxicity:
METH enters the DAergic terminal partially by diffusion but mostly via DAT, which sees
METH as a substrate (Schuldiner, Steiner-Mordoch et al. 1993). After entering the terminal by
DAT-mediated active translocation, METH disrupts the function of DAT by various mechanisms.
METH is known to cause DA efflux in the synapse by DAT reverse transport (Figure 1.6). It has
also been shown to cause internalization of DAT into endosomes (Kahlig, Binda et al. 2005,
Fleckenstein, Volz et al. 2007). Once in the terminal, METH releases DA from the vesicles. This
free DA auto-oxidizes and produces free radicals which oxidize and inactivate DAT (Berman,
Zigmond et al. 1996, Fleckenstein, Metzger et al. 1997). Fleckenstein and colleagues
(Fleckenstein, Haughey et al. 1999) have shown that METH decreases the function of DAT in
vivo. Two theories exist about the mechanism by which METH releases vesicular DA:
(1)

Weak base hypothesis: METH enters the vesicles via lipophilic diffusion.

The pH of the vesicles is maintained at 5-5.7 at all times. This acidic pH is very important
for transport of DA into the vesicles from the cytosol against the concentration gradient.
Like all amphetamines, METH is a weak base which protonates in acidic medium. Once
in protonated state, it accumulates in acidic environment. Due to protonation of METH,
there is depletion of protons in the vesicles which alters the acidic pH of the vesicles
(Lee, Gubernator et al. 2010, Sulzer 2011).
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(2)

Substrate of VMAT2: This hypothesis states that METH acts as a substrate

of VMAT2 and enters the vesicles. It is not completely clear whether METH is a direct
substrate of VMAT2; however, METH does competitively inhibit the uptake of DA by
VMAT2 into the vesicles. Thereafter, it disrupts the vesicular pH gradient and releases
DA. This theory is supported by several previous studies which show preferential binding
of VMAT2 towards substituted amphetamines (Schuldiner, Steiner-Mordoch et al. 1993,
Gonzalez, Walther et al. 1994, Peter, Jimenez et al. 1994, Reith and Coffey 1994).
Apart from affecting DAT and VMAT2, METH is known to decrease the activity of TH
(Hotchkiss and Gibb 1980) and inhibit DA metabolism by antagonizing the actions of
monoamine oxidase (MAO), an enzyme responsible for metabolism of monoamines. This way
there is more of cytosolic DA for reverse transport as well as autooxidation (Sulzer 2011).

Figure 1.6: METH produces neurotoxicity via various mechanisms: main
being oxidative stress, excitotoxicity and mitochondrial dysfunction (Tata
and Yamamoto 2007).
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Figure 1.7: Mechanism of METH neurotoxicity. METH enters the
dopaminergic (DAergic) nerve terminal as a substrate of dopamine
transporter (DAT) and via passive diffusion. Once inside the terminal, it
releases DA from the storage vesicles by impairing the function of vesicular
monoamine transporter 2 (VMAT2) and via collapsing proton gradient
across the vesicular membrane after diffusing into the vesicles (Sulzer
2011).

An early event of METH neurotoxicity is autooxidation of released DA with the
-.

-

production of several reactive oxygen species (ROS) (H2O2, O2, O2 , OH, OH and DA quinones).
Along with oxidative stress, nitrosative stress also plays role in METH neurotoxicity. The
generated free radicals lead to accumulation of oxidized proteins and lipid peroxidation
products. Moreover, the DA quinones covalently modify cysteinyl residues of proteins which
cause selective toxicity to DAergic terminals (LaVoie and Hastings 1999, Tata and Yamamoto
2007).
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Figure 1.8: Oxidation products of DA. Autooxidation of DA leads to
production of several reactive oxygen species, including free radicals,
quinones (SQ°, Q), and hydrogen peroxide. These by-products
oxidatively damage proteins and other cellular components to cause
nerve terminal loss (reproduced from Dr. Anna Moszczynska’s
presentation).

A.

Oxidative stress and DA: Owing to the selective toxicity of METH to

DAergic and 5HT terminals, DA mediated oxidative stress is believed to be one of the
major mechanisms of METH toxicity. METH acts by producing ROS, reactive nitrogen
species (RNS) and lipid peroxidation products. Moreover, as per the weak base
hypothesis, amphetamines disrupt the proton gradient of the vesicles and stimulate
efflux of neurotransmitters from the vesicles (Sulzer and Rayport 1990, Pifl, Drobny et
al. 1995). As a result, free DA is released in the cytoplasm of the nerve terminal. Free DA
autooxidizes to produce ROS and quinones which lead to oxidative stress (Yamamoto,
Moszczynska et al. 2010) (Figure 1.8). This theory has been proved by the protective
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effect produced by pretreatment with antioxidants like ascorbic acid and vitamin E (Vito
and Wagner 1989). Increased levels of ROS as well as increase in antioxidants like
glutathione (both reduced and oxidized form) as a compensatory mechanism at 2 h
after binge METH has been reported in rats (Harold, Wallace et al. 2000). However,
another study that used higher doses of binge METH reported a decrease in total
glutathione levels at 3 h after the last METH injection, suggesting overutilization of GSH
(Moszczynska, Turenne et al. 1998).
B.

Excitotoxicity: METH causes an increased release of glutamate in the

striatum which, in turn, causes increased glutamate receptor activation (Nash and
Yamamoto 1992). Glutamate release causes activation of NMDA and non-NMDA
receptors and increases production of nitric oxide (NO) and superoxide radicals via
calcium mediated pathway (Gunasekar, Kanthasamy et al. 1995). Nitric oxide and
superoxide radicals interact to produce the neurotoxin peroxynitrite (Pacher, Beckman
et al. 2007). End process involves nitration of proteins and damage to mitochondria,
endoplasmic reticulum and deoxyribonucleic acid (DNA) (Yamamoto, Moszczynska et al.
2010).
C.

Hyperthermia: Apart from being a stressor by itself, hyperthermia is an

important component augmenting METH neurotoxicity. Hyperthermia-mediated
production of free radicals, disruption of DAT, TH and ubiquitin proteasome system
increase the severity of METH toxicity. Increase in the rates of all enzymatic processes at
high temperature would explain the above effect (Bowyer, Davies et al. 1994,
Yamamoto, Moszczynska et al. 2010). This is consistent with the finding that inhibiting
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hyperthermia reduces free radical formation and subsequent damage to DAergic
terminals (Fleckenstein, Wilkins et al. 1997).
D.

Mitochondrial dysfunction is another contributor to METH neurotoxicity.

After diffusion into the mitochondria, METH accumulates there. Here, it alters
mitochondrial membrane potential, decreases the function of the mitochondrial
complexes and hinders the production of ATP (Davidson, Gow et al. 2001). This is
followed by the release of cytochrome c to the cytosol as well as activation of caspasemediated apoptotic pathways in both cell bodies (SNPc, striatum) and terminals
(striatum). These effects, along with low ATP levels in the brain, cause mitochondrial
damage and toxicity (Burrows, Gudelsky et al. 2000).
E.

Inflammation is also one of the several mechanisms of METH toxicity.

METH-induced inflammatory response is mediated by several pathways. METH releases
glutamate, which activates microglia in rat striatum. Moreover, DA quinones, which are
products of autooxidation of DA, also activate microglia. These activated microglia
release pro-inflammatory molecules. Increased glutamate receptor activation enhances
production of interleukins (IL-1β and IL-6) and tumor necrosis factor (TNF-α)
(Yamamoto, Moszczynska et al. 2010).
F.

Damage to the Ubiquitin proteasome System (UPS):

The ubiquitin proteasome system serves as a scavenger for damaged and
misfolded proteins or those proteins which are no longer needed. In this system, the
proteins to be degraded are tagged with a 76 amino acid protein ubiquitin. This process
is brought about by 3 enzymes:
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Ubiquitin activating enzyme E1



Ubiquitin conjugating enzyme E2



Ubiquitin ligase E3, which ligates ubiquitin to the substrate protein.

There are different types of E3 ligases in various regions of the body. After the first
ubiquitin is ligated, a polyubiquitin chain is formed on the substrate, which marks it for
degradation by the 26S proteasome.
The mammalian 26S proteasome comprises of two components:
1.

A 20S core with catalytic sites for proteases. It can even degrade oxidized

proteins in the ubiquitin-independent manner.
2.

Two 19S regulatory caps that deubiquitinate the substrate preparing it

for degradation in the 20S core (Hershko A 1998).
High doses of binge METH decrease the activity of 26S proteasome in striatal
synaptosomes from adult rats. Furthermore, binge METH oxidatively damages parkin and
decreases its levels in these rats (Moszczynska and Yamamoto 2011) as well as in late
adolescent rats exposed to binge METH (Killinger, Shah et al. 2014). Out of the 600 E3 ligases
present in neurons, parkin is known to be greatly affected by METH. Parkin has many substrates
such as alpha-synuclein, CDCrel-1, alpha-tubulin, synaptotagmin and others. Without parkin,
there would be an abnormal accumulation of the above substrates leading to toxicity. Thus,
parkin deficit and dysfunction of the proteasome can lead to build up of damaged proteins and
contribute to METH neurotoxicity. In support of this notion, overexpression of parkin was found
to protect DAergic terminals in the striatum from METH neurotoxicity (Liu, Traini et al. 2013).
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1.5 Vesicular monoamine transporter 2 in METH neurotoxicity:
1.5.1 VMAT2 structure and function:
VMAT2 is a member of the TEXANs (toxin extruding antiporter system) family. VMAT2
has a role of extruding free DA and other monoamines from the cytoplasm into the vesicles in
exchange of protons (Martin, Schafer et al. 2013). VMAT2 is derived from the gene SLC18A2. It
is an acidic glycoprotein with 3 isoforms: native form (45 kDa), partially glycosylated form (55
kDa) and fully glycosylated form (75 kDa). It is a transmembrane protein containing 12
transmembrane domains with both C and N terminals in the cytosolic part of the vesicle (CruzMuros, Afonso-Oramas et al. 2008, Wimalasena 2011) (Figure 1.9). VMAT2 is expressed in
various monoaminergic cells in the brain, mast cells and histamine containing gut cells (Weihe,
Schafer et al. 1995). Within the brain, striatum and hypothalamus are rich in VMAT2. The
primary function of VMAT2 is to sequester monoamines from the cytosol of the nerve terminal
and package it into synaptic vesicles. It maintains a high neurotransmitter concentration inside
the vesicles by transporting monoamines against the concentration gradient. The energy for
this transport is derived from the acidic pH gradient maintained inside the vesicles (Wimalasena
2011). The function of VMAT2 is extremely important for proper presynaptic function. Evidence
for this is obtained by studies on homozygous VMAT2 knockout mice, which do not survive
more than few days after birth due to improper monoamine storage and exocytotic release.
Also, in VMAT2 heterozygous mice, decreased extracellular DA levels and high sensitivity to
METH and other psychostimulants is observed (Wang, Gainetdinov et al. 1997). Another study
showed that VMAT heterozygous mice had more neurotoxicity as compared to wild type mice
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(Fumagalli, Gainetdinov et al. 1999). Thus, VMAT2 plays an important role in neurotransmitter
release and the mechanism by which psychostimulants produce neurotoxicity.

Figure 1.9: Structure of the vesicle monoamine transporter 2 (VMAT2). It
has 12 transmembrane domains with both C and N terminals in the
cytosol (Wimalasena 2011).

1.5.2 VMAT2 and the synaptic vesicle cycle:
Synaptic vesicles loaded with neurotransmitters travel to the membrane in response to
action potential. At the membrane, they dock and prime to release DA in the synapse. After
docking, DA is released by exocytosis. Following exocytosis, one of the three phenomena can
occur:
(1) The empty vesicles do not undock and they are loaded with neurotransmitter again.
These vesicles constitute the readily releasable pool of vesicles.
(2) The empty vesicles undock and recycle back to the cytosol where they are loaded with
neurotransmitter
(3) The vesicles undergo clathrin-mediated endocytosis and get filled with neurotransmitter
again via an endosomal compartment.
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Recycling of VMAT2 vesicles is important as this leads to reloading of vesicles for the
new exocytotic cycle (Sudhof 2004).
1.5.3 VMAT2 in neuroprotection and neurotoxicity:
VMAT2 is an integral protein of the membrane of the monoamine storage synaptic
vesicles. Its main function is to sequester monoaminergic neurotransmitters like DA, 5HT,
norepinephrine and histamine from cellular cytosol into vesicles (Eiden, Schafer et al. 2004). At
molecular level, one of the key manifestations of METH toxicity is the dysfunction of VMAT2 in
the striatum. Thus, a decrease in vesicular DA uptake capacity of striatal VMAT2 has been
observed as early as 1 h after binge METH in rats (Brown, Hanson et al. 2000). In mice, binge
METH caused a decrease in VMAT2 ligand binding 6 days after METH treatment (Hogan, Staal et
al. 2000). Toxic doses of METH also cause an altered subcellular distribution of VMAT2. At 1 h
following METH, immunoreactivity of the partially glycosylated form of VMAT2 (~55 kDa)
decreases in cytosolic fraction of synaptosomes with either an increase or no change in the
membrane fraction in mice (Ugarte, Rau et al. 2003) and rats (Riddle, Topham et al. 2002),
respectively. Compared to saline controls, the glycosylated form of VMAT2 (~68 kDa) also
decreases in the cytosolic fraction at 1 h after the last METH injection in the rat striatum. At 24
h after binge METH, the immunoreactivity of the glycosylated isoform of VMAT2 was found to
decrease in all synaptosomal fractions (Eyerman and Yamamoto 2005). These results suggest
either degradation of VMAT2 or its mobilization to a non-synaptosomal compartment,
potentially by a retrograde transport of damaged VMAT2 to the SNPc. A suggested possibility
was damage to VMAT2 by nitrosative stress. Eyerman and colleagues showed nitrosylation of
VMAT2 (~68 kDa) 1 h after METH and that the short term (1 h) and long term (7 days) decreases
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in immunoreactivity of VMAT2 could be reversed by pretreatment with a nitric oxide synthase
inhibitor (Eyerman and Yamamoto 2007). Thus, a number of studies have shown dysfunction of
VMAT2 following binge METH regimen.
Especially in the DAergic systems, VMAT2 plays a neuroprotective role by sequestering
free DA from cellular cytosol into storage vesicles at nerve terminals. The acidic pH in these
storage vesicles protects the terminals from the oxidative damage caused by free radical
products of DA autooxidation. VMAT2 transfection into PC12 cells lowered the cell death
caused by METH (Vergo, Johansen et al. 2007). Further studies have shown that DA receptor
agonists like pramipexole (a D2/D3 receptor agonist) and apomorphine (a D1/D2 receptor
agonist) which are used to treat symptoms caused by DAergic nerve degeneration, increase
the DA uptake capacity of VMAT2. This means that restoring or enhancing the function of
VMAT2 can be used as a treatment for neurodegenerative conditions (Truong, Rau et al. 2003,
Truong, Hanson et al. 2004). In METH toxicity study, the VMAT2 ligand lobeline was found to
inhibit METH-mediated release of DA from the synaptic vesicles in vivo (Eyerman and
Yamamoto 2005). Moreover, pre-treatment by lobeline was found to decrease METH selfadministration in rats (Harrod, Dwoskin et al. 2001). Thus, VMAT2 plays an important role in
neuroprotection and is an emerging target for development of treatments for METH toxicity
and other neurodegenerative conditions (Harrod, Dwoskin et al. 2001, Dwoskin and Crooks
2002).

1.6 Parkin in METH neurotoxicity:
1.6.1 Parkin structure and function:
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Parkin is a ring-between-ring ring protein (RBR), which belongs to a group of 12
multidomain enzymes. The parkin gene encodes for the protein parkin, which has 5 domains, 4
out of which are zinc binding domains and one is homologus to ubiquitin (Byrd and Weissman
2013, Spratt, Walden et al. 2014). The N terminal of parkin shows homology to ubiquitin and
the C terminal has two ring finger motifs with an in-between ring finger domain (IBR) (Morett
and Bork 1999). The IBR and ring finger motifs are believed to be binding sites for the ubiquitinconjugating enzymes E2 (Figure 1.10). Parkin is made up of 465 amino acids and has a
molecular weight of 52 kDa. Expression of parkin occurs in multiple organs like brain, heart,
testis and skeletal muscle. Within the brain, it is found in many regions such as striatum, SNPc,
cerebellum and hippocampus (Oliveras-Salva, Rompuy et al. 2011). Parkin functions primarily as
an E3 ligase in the ubiquitin proteasome system. E3 ligases ligate the polyubiquitin chains to
substrate proteins and mark them for degradation by the proteasome. Parkin self-ubiquitinates
itself and regulates its own levels. A number of parkin substrates have been identified. Of major
interest for us being the septin CDCrel-1. Parkin directly interacts with CDCrel-1 via its ring
finger domain and controls the turnover of the protein (Zhang, J Gao et al. 2000). Other
substrates of parkin are Pael-R, alpha synuclein, synphilin-1, alpha-tubulin and many others
(Cookson 2003). Previous studies have shown that METH oxidatively damages parkin as well as
the 26S proteasome along with reducing parkin mRNA levels (Nakahara, Kuroki et al. 2003,
Moszczynska and Yamamoto 2011).
Parkin knockout mice show no differences in brain morphology, weight and size as
compared to controls (Itier, Ibáñez et al. 2003). No loss of DAergic neurons or their striatal
projections was observed until 24 months of age; however, decreases in DAT and VMAT2
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binding activity were observed. Small differences were observed in the DAergic
neurotransmission and variable data exists regarding DA metabolism in different studies. Also,
inhibition of METH-induced DA release was observed. This suggests lowering of DAergic density
in the absence of parkin. Parkin knockout rats also showed no pathological changes. However,
at 8 months of age, they showed a 20% reduction in TH positive neurons in SNPc (Itier, Ibáñez
et al. 2003, Sato, Chiba et al. 2006, Oliveras-Salva, Rompuy et al. 2011, Dave, Silva et al. 2014).

Figure 1.10: Schematic representation of the structure of parkin. The ubiquitin
like N terminal of the protein and the ring finger motifs with in-between ring
finger (IBR) have been demonstrated in parkin (Riley, JC Lougheed et al. 2013).

1.6.2 Parkin in neurotoxicity and neuroprotection:
METH induced oxidative stress causes neurotoxicity via multiple mechanisms. Loss of
parkin function has been related to Parkinson’s disease (Matsumine, Saito et al. 1997) and
METH neurotoxicity. Parkin has been implicated in both autosomal recessive juvenile
Parkinson’s disease (AR-JP) and idiopathic Parkinson’s disease. Loss of parkin function due to
mutation in parkin gene leads to AR-JP (Shimura, Hattori et al. 1999), whereas loss of parkin
function and accumulation of parkin substrate alpha-synuclein and formation of Lewy bodies is
believed to be one of the causes for idiopathic form of the disease (Choi, Golts et al. 2001).
METH damages parkin and decreases its levels (Moszczynska and Yamamoto 2011). The DA
released by METH covalently modifies parkin and disrupts its function (LaVoie, Ostaszewski et
al. 2005). Oxidative stress is also known to alter the solubility of parkin and cause parkin
monomers to aggregate into insoluble non-functional polymers (LaVoie, Ostaszewski et al.
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2005). Binge METH has been shown to oxidatively damage parkin as early as 1 h after the last
dose of METH. These decreases in the immunoreactivity of parkin persisted up to 24 h
returning to basal levels at 48 h (Moszczynska and Yamamoto 2011).
Parkin protects against a number of stresses. Overexpression of parkin in cells treated
with proteasomal inhibitors showed significant protection from damage caused by
dysfunctional proteosome (Petrucelli, O'Farrell et al. 2002). Other studies have shown that
overexpression of parkin protects cells from death due to excitotoxicity and toxicity caused by
Pael-R or alpha-synuclein (Feany and Pallanck 2003). Darios and colleagues showed that parkin
protects from mitochondrial death by prevention of mitochondrial swelling and release of
cytochrome c (Darios, Corti et al. 2003). Parkin has also been found to play a neuroprotective
role in the toxicity produced by METH. Enhancing parkin function could play a protective role
by scavenging damaged protein aggregates. More recently, our lab published that parkin
overexpression in rat nigrostriatal system protects against METH induced decreases in striatal
TH (Liu, Traini et al. 2013). The molecular mechanism by which parkin protects against METH
toxicity is unknown.

1.7 Septins:
1.7.1 Structure and function:
Septins are a family of proteins that function as GTPases. They have a GTP binding
domain present in each protein. They play role in a variety of biological conditions like
cytokinesis, vesicle dynamics & exocytosis, neoplasia, infection, hemostasis, neuropathology
and neurodegenerative diseases. Septin polypeptides are found to complex and form filament
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or ring like higher order structures (Roeseler, Sandrock et al. 2009). Septins have been found
to interact with the rSEC6/8 exocyst complex (a multi-protein complex which interacts with
vesicular docking proteins to play a role in release of neurotransmitters), which is believed to
play a regulatory role in exocytosis (Hsu, Ting et al. 1996, Hsu, Hazuka et al. 1998). CDCrel-1 is
a septin, which is mostly expressed in the brain and present in very small amounts in nonneuronal cells. It comprises about 0.1 percent of the total proteins in the brain. In mouse
brain, CDCrel-1 has been observed to localize around the presynaptic vesicles (Kinoshita, Noda
et al. 2000). Within the human brain, the protein CDCrel-1 has been found in all regions with
higher expression in cortical areas and lower in sub-cortical regions such as hippocampus,
putamen and thalamus (Caltagarone, Rhodes et al. 1998). Despite the fact that it lacks a
transmembrane domain, CDCrel-1 is found attached to membrane and synaptic vesicles. It has
also been found that CDCrel-1 binds to syntaxin, which is a part of the soluble Nethylmaleimide sensitive fusion protein (NSF) attachment protein (SNAP) Receptor complex
(SNARE). By this interaction, it prevents docking of vesicles to the membrane and prevents
exocytosis (Beites, Xie et al. 1999). Interestingly, CDCrel-1 is a substrate of the E3 ligase parkin.
Parkin interacts with CDCrel-1 via its ring finger domain and augments its turnover mediated
by the UPS (Zhang, J Gao et al. 2000).

1.7.2 CDCrel-1 in neurotoxicity:

CDCrel-1 inhibits exocytosis by interacting with the SNARE complex. Role in exocytosis
is believed to be the primary function of CDCrel-1 in mammals (Beites, Xie et al. 1999). Under
basal conditions, the levels of CDCrel-1 are maintained at a very low level in DAergic neurons
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as compared to GABAergic neurons (Kinoshita, Noda et al. 2000). However, under abnormal
conditions, such as diminished function of parkin, this protein accumulates in cells (Zhang, J
Gao et al. 2000). The overexpression of CDCrel-1 showed DAergic neuron specific loss in the
SNPc and decline of striatal DA in rat brain. No damage by CDCrel-1 expression was observed
in the globus pallidus. This DAergic selective loss could be prevented by co-expression of
parkin (Zhizhong Dong 2003). It is not clear how the accumulation of CDCrel-1 can be
selectively toxic to DAergic system. Mechanisms have been suggested for this phenomenon. It
was observed that inhibition of TH and DA synthesis prevented the neurodegeneration by
CDCrel-1. This means that CDCrel-1 produces DA-dependent neurotoxicity and that
augmentation of DA synthesis could be the cause for its damaging effect. This speculation
would account for why only DAergic specific toxicity is observed by CDCrel-1 overexpression.
Also, CDCrel-1 inhibits the exocytosis of DA. This impairment in the neurotransmission of DA
and possible oxidative damage due to increased free DA in the terminal could also be
responsible for neurodegeneration (Dong, Ferger et al. 2003). None of the above speculations
have been proven to be the mechanism by which CDCrel-1 causes DAergic toxicity.

1.8 Rationale:
Despite the extensive research in the area of METH neurotoxicity, no treatment regimen
or medication to cure METH-induced brain damage are available. Current medications used in
emergency rooms only provide symptomatic relief from METH overdose. There are no
treatments to prevent, inhibit or reverse METH toxic effects on the brain. Thus, there is an
immediate need for effective treatment to cure METH damage to the brain. Consequently, new
molecular drug targets are needed to develop new pharmaceuticals.

32

E3 ligase parkin protects striatal DAergic terminals against METH neurotoxicity.
Therefore, parkin is a potential drug target for therapeutic interventions in human METH users,
particularly those who take METH in high doses. Furthermore, no studies to date examined the
role of parkin in regulation of VMAT2-bearing vesicle trafficking in vivo. The important role of
proper VMAT2 function and VMAT2 vesicle trafficking in DA neuron homeostasis has been
established.
Many studies have shown the dysfunction of VMAT2 function and trafficking following
METH. Although the decrease in cytosolic fraction was shown, none of the studies observed a
decrease in the VMAT2 immunoreactivity at the membrane. Previous study has shown a
redistribution of VMAT2 from membrane to cytosol upon D2 receptor activation (Truong,
Newman et al. 2004). Since METH indirectly acts as a D2 agonist by releasing DA, we would
expect a decrease in VMAT2 at the membrane following METH treatment. This suggests VMAT2
might be retained at the membrane of the terminal, possibly trapped via filamentous proteins
(Hirokawa, Sobue et al. 1989). However, whether VMAT2 is trapped at the plasma membrane
and by what mechanism has not been determined.
As an E3 kigase, parkin regulates the turnover of many proteins and thereby protecting
the cell against damage by aggregated or misfolded proteins. CDCrel-1 is one of the several
substrates of parkin. Following insult by METH, there is a decrease in parkin levels which could
lead to accumulation of CDCrel-1 (Dong, Ferger et al. 2003, Moszczynska and Yamamoto 2011).
Why accumulation of CDCrel-1 is responsible for neurodegeneration is unclear. Accumulation of
other substrates of parkin such as Pael-R and alpha-synuclein is also found to cause

33

neurodegeneration (Dusonchet, Bensadoun et al. 2009, Perren, Toelen et al. 2014). Parkin is
one of several hundred E3 ligases in neurons. To the best of our knowledge, the regulation of
CDCrel-1 by an E3 ligase other than parkin has not been found. The mechanism by which
CDCrel-1 accumulation leads to DAergic neurodegeneration needs to be determined.

1.9 Hypothesis and specific aims:
METH, a widely used drug of abuse, is neurotoxic to DAergic terminals in the striatum.
This neurotoxicity, mainly, in part, is due to lack of cytosolic DA sequestration by synaptic
vesicles. The autooxidation of this unsequestered DA leads to oxidative stress and
neurodegeneration of the terminals. VMAT2 plays a neurprotective role by transporting
cytoplasmic DA into vesicles for storage and protection from oxidation. It has previously been
shown that METH toxicity is associated with impaired VMAT2 trafficking and a decrease in the
levels of E3 ligase parkin in striatal synaptosomes at 1 h and 24 h time points (Riddle, Topham
et al. 2002, Moszczynska and Yamamoto 2011). Parkin regulates the levels of CDCrel1, a protein
found to inhibit exocytosis and induce neurodegeneration to DA neurons (Zhang, J Gao et al.
2000, Chu, Hadlock et al. 2010). At present, the interactions between CDCrel-1, VMAT2 and
parkin in METH toxicity are not known. Since the impaired trafficking of VMAT2 as well as the
deficit in parkin mediated by binge METH have been studied at 1 h and 24 h after the last
injection of the drug, we decided to limit our study to these two time points.
The goal of the present study was to test the hypothesis that METH-mediated parkin
deficit results in accumulation of CDCrel-1 within DAergic terminals, which in turn causes an
entrapment of VMAT2 vesicles at the plasma membrane, preventing their recycling and proper
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sequestration of cytosolic DA. As mentioned previously, septins form filamentous structures
that might be responsible for entrapment of VMAT2 by physical occlusion (Figure 1.11). Based
on the available data, the following chain of events was hypothesized to occur after binge
METH administration:
(1) The levels of parkin decrease 1 h and 24 h following the last METH dose
(2) The levels of CDCrel-1, the substrate of parkin, will elevate at the same times following
METH
(3) VMAT2 vesicles will be entrapped in CDCrel-1 filaments and will not be recycled back
to the cytosol at 1 h and/or 24 h
(4) Intracellular DA sequestration will decrease following METH neurotoxicity
(5) Overexpression of parkin will decrease CDCrel-1 levels and restore VMAT2 trafficking

(A)
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(B)

Figure 1.11 Hypothesized events: Release of DA and VMAT2 trafficking under
basal (A) and METH conditions (B). DA containing vesicles recycle back to the
cytosol after exocytosis to reload neurotransmitters for the next cycle. Binge
METH alters the trafficking of VMAT2. We hypothesize that binge METH causes
the vesicles to be trapped at the membrane by the protein CDCrel-1.

Specific Aims:
(1) To determine the immunoreactivity of parkin, CDCrel-1 and VMAT2 in synaptosomal
fractions from the striatum following binge METH
(2) To elucidate whether VMAT2 interacts with CDCrel-1 and whether VMAT2 remains
trapped at the membrane following METH
(3) To establish whether parkin plays a protective role in METH induced neurotoxicity via
restoration of proper VMAT2 trafficking.

36

CHAPTER 2: MATERIALS AND METHODS
2.1 Animals
Adult male Sprague–Dawley rats (Harlan, Indianapolis, IN, USA) (PND>60 days), were
pair-housed under a 12 h light/dark cycle in a temperature- and humidity-controlled room.
Food and water were available ad libitum. Temperature of the rats was measured via a rectal
probe digital thermometer (Thermalert TH-8; Physitemp Instruments, Clifton, NJ). All animal
procedures were conducted in strict accordance with the NIH Guide for Care and Use of
Laboratory Animals and approved by the Institutional Animal Care and Use Committee at
Wayne State University (# A06-03-10 and # A05-07-13).

2.2 Drug Treatment
(+)-Methamphetamine, free-base (METH) (Sigma- Aldrich, St. Louis, MO) or saline were
administered to rats in the following binge regimen: METH: (8 mg/kg) or saline (1 ml/kg) was
administered to rats in four successive intraperitoneal (i.p.) injections, 2 hours apart. Rats were
sacrificed by decapitation at 1 h or 24 h after the last injection of METH or saline. Core body
temperature was monitored before the treatment as well as 1 h after each dose of METH or
saline. Striata and cerebella were harvested immediately following the euthanasia and stored at
-80°C until analyzed.

2.3 Preparation and fractionation of synaptosomes
The harvested tissue samples were homogenized in 500 µl of ice cold 0.32 M sucrose
solution with 13 strokes, using a dounce homogenizer (Wheaton, USA). The homogenates were
first centrifuged at 800 x g for 24 min at 4°C. Nuclei and other debris (P1) were discarded and
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the supernatants (S1) were again centrifuged (22,000 x g for 17 min, 4°C) to obtain total
synaptosomal pellets (P2). The P2 pellets were resuspended in 150 µl of distilled deionized
water (ddH2O) giving total synaptosomal fractions. A volume of 50 µl of this total synaptosomal
fraction was aliquoted from each sample for further analysis. The remaining 100 µl was
centrifuged (22,000 x g for 17 min, 4°C) to obtain cytosol-vesicular (S3) and membraneendosomal (P3) fractions. The P3 pellets were resuspended in 100 µl of ddH2O. Synaptosomal
preparations were analyzed for protein concentration by Bradford protein assay using bovine
serum albumin (BSA) as the standard. All samples and resulting fractions were kept on ice at all
times prior to analyses. For all future references, P2 fraction is referred to as the total
synaptosomal or total fraction, P3 is referred to as the membrane fraction and S3 is referred to
as the vesicular or cytosolic fraction.

2.4 Electrophoresis and Western Blotting
Synaptosomal fractions (total, membrane and cytosolic) were subjected to reducing
sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) under denaturing and
reducing conditions (with beta-mercaptoethanol added as a reducing agent to the sample
loading buffer). The amount of 10-20 μg proteins were loaded per lane on 4-12% Bis-Tris gels
(Life Technologies, Grand Island, NY). The gels were run for 1 h at room temperature at 150V
using an Invitrogen apparatus. All proteins were transferred to PVDF membranes (EMD
Millipore, Billerica, MA) at 400 mA and then blocked for 1 h at room temperature with 3% nonfat dried milk dissolved in TBST (10 mM Tris, 150 mM NaCl, and 0.05% Tween-20). The
membranes were then probed with either mouse monoclonal primary antibodies against
CDCrel-1 (1:1000, overnight at 4°C) (MAB5358; Chemicon International, Temecula, CA), parkin
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(1:1,000; overnight at 4°C) (Prk8; Cell Signaling Technology, Danvers, MA), actin (1:1,000; 1 h at
room temperature) (8H10D10; Signaling Technology, Danvers, MA), alpha-tubulin (1:1000,
overnight at 4°C) (sc58668; Santa Cruz Biotech, Santa Cruz, CA, USA), or rabbit polyclonal
primary antibody against VMAT2 (1:3000, overnight at 4°C) (NBP1-69750H, Novus Biologicals).
The incubations with primary antibodies were followed by washing (3 times for 5 min) with
TBST followed by incubations with appropriate horseradish peroxidase (HRP)-conjugated
secondary antibodies (1:10,000 for 1 h at room temperature). Blots were developed using ECL
detection and LAS4000 bioimager (GE Healthcare, Piscataway, NJ). For standardization across
blots, each blot contained all experimental groups. The western blot data was expressed as
relative optical density units on each gel normalized to saline controls. This approach
normalized differences in the development of the blot and across blots.

2.5 Loading Control
Actin and alpha-tubulin are components of microtubules and present in high abundance
in cells. Consequently, they are widely used as loading controls. We observed a change in the
levels of actin at 1 h after binge METH in both membrane as well as vesicular fractions. So, actin
did not prove to be a good loading control for our study. There was no change in actin levels at
24 h time point. Along with actin, we also assessed the levels of alpha-tubulin at 1 h and 24 h
after METH. Alpha-tubulin levels also changed following METH. To be accurate and consistent,
we used Ponceau S (P7170, Sigma- Aldrich, St. Louis, MO) as a loading control for the duration
of the entire study. The detailed description of these findings is included tin the Results section.
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2.6 Immunoflorescence
Synaptosomes were isolated from the striatum of saline-treated and METH-treated rats.
The total synaptosomal pellet was resuspended in permeabilization buffer (0.32M sucrose,
0.01% digitonin, 1 x HALT, 1mg/mL BSA) and gently inverted at 4°C for 1 h. Antibodies to parkin
(1:250) (Prk8; Cell Signaling Technology, Danvers, MA) and TH (1:250) (AB152, EMD Millipore
Corp., Billerica, MA) were subsequently added to the re-suspended synaptosomes and
incubated under gentle agitation at 4°C overnight. Samples were then centrifuged at 22,000 x g
for 5 min at 4°C and the supernatant carefully discarded. The resulting pellet was gently washed
in permeabilization buffer 3 times for 10 min at 4°C. Between each wash the samples were
centrifuged at 22,000 x g for 5 min to pellet the synaptosomes and supernatant was carefully
discarded. Following the final wash, the synaptosomal pellet was re-suspended in
permeabilization buffer containing Alexa 488 donkey anti-mouse (1:150) (A-21202, Life
Technologies Corp., Carlsbad, CA) and donkey anti-rabbit Alexa 594 (1:150) (A-21207, Life
Technologies Corp., Carlsbad, CA). Following the addition of secondary antibody all samples
were protected from light until imaging. Samples were incubated with secondary antibody
under gentle agitation at 4°C for 2 h. The samples were then washed as previously described.
The final synaptosomal pellet was then re-suspended in 300 µl of permeabilization buffer and 5
µL samples were aliquoted onto frosted microscope slides (Fisherbrand, Thermo Fisher
Scientific Inc., Waltham, MA). The samples were allowed to settle and dry for 4 h at room
temperature. The slides were then mounted with Fluoromount-G™ mounting media (0100-01,
SouthernBiotech, Birmingham, AL) and allowed to dry overnight. Slides were then examined
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for fluorescence using confocal microscopy (Leica TCS SPE, Leica Microsystems, Wetzlar,
Germany).

2.7 Co-Immunoprecipitation
Striatal synaptosomal fractions were prepared from rats euthanized at 1 h time point
following saline or METH treatment. Dynabeads (Life Technologies, Grand Island, NY) were
incubated in the presence of 2 μl of either a rabbit polyclonal VMAT2 primary antibody (NBP169750H, Novus Biologicals), mouse monoclonal CDCrel1 primary antibody (MAB5358;
Chemicon International, Temecula, CA), parkin monoclonal primary antibody (Prk8, 1:1000; Cell
Signalling Technology), or radioimmunoprecipitation assay (RIPA) buffer (negative control) for
6–12 h at 4°C, followed by the addition of synaptosomal fractions (100-200 µg) and second
incubation (12 h at 4°C). For all quantitative co-immunoprecipitation studies, equal protein
content of synaptosomal fraction was incubated with beads for each representing group (saline
or METH). Following each incubation, the beads were washed three times using phosphate
buffered saline with Tween-20 (PBST, 0.02% Tween-20). Following immunoprecipitation, Parkin,
CDCrel1 or VMAT2 protein was dissociated from the beads using SDS Tris–Glycine sample
buffer (Bio-Rad, Hercules, CA, USA) and heating (10 min at 70°C). The supernatants from the
beads were run on 4-12% Bis-Tris gels under reducing conditions and subjected to western blot
analysis using parkin, VMAT2 and CDCrel1 antibodies and appropriate secondary antibodies, as
described above (section 2.4).
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2.8 Mass Spectrometry
Membrane fractions of synaptosomes were incubated with Dynabeads conjugated with
VMAT2 antibody and processed as described for co-immunoprecipitation. The resulting eluted
samples were run on a gel and the gel was stained with Sypro Ruby stain. Gel slices were
excised from a Sypro Ruby-stained gel and the slices were washed and digested. The gel pieces
were first washed with water and 25 mM NH4HCO3, 50% acetonitrile for 15 min each. The
liquid was removed and the gel pieces were dehydrated in 100% acetonitrile for 5 min. Once
the liquid was removed, the gel pieces were rehydrated in 50 mM NH4HCO3. After 5 min, an
equal volume of 100% ACN was added and the gel pieces were left to incubate in the solution
for another 15 min. All liquid was then removed and the gel pieces were dehydrated once
again in 100% acetonitrile for 5 min. Once the liquid was removed after the incubation, the gel
pieces were speed vacuum dried for 5 min. The following reactions were then performed:
reduction with 5 mM dithiothreitol in 50 mM NH4HCO3, alkylation with 15 mM indoleacetic acid
in 50 mM NH4HCO3, and overnight digestion with sequencing-grade trypsin (Promega, Madison,
WI) in 25 mM NH4HCO3/10% ACN. Following digestion, peptides were extracted from the gel
plugs using 50% acetonitrile/0.05% formic acid. The free peptides were then speed vacuumed
to dryness and solubilized in 2% acetonitrile/0.1% formic acid.
The peptides were separated by a reverse phase chromatography (Acclaim PepMap
RSLC C18 column, Thermo Scientific, Waltham, MA), followed by ionization with the Nanospray
Flex Ion Source (Thermo Scientific), and introduced into a Q Exactive mass spectrometer
(Thermo Scientific).

Abundant species were fragmented with high-energy collision-induced

dissociation (HCID). Data analysis was performed using Proteome Discoverer 1.4 (Thermo
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Fisher, Waltham, MA), which incorporated the Mascot algorithm (Matrix Science). The Swiss
Prot_2013_03 database was searched against rat protein sequences and a reverse decoy
protein database was run simultaneously for false discovery rate (FDR) determination.
Secondary analysis was performed using Scaffold 4.2.1 (Proteome Software). Minimum protein
identification probability was set at >=95% with 2 unique peptides at >=99% minimum peptide
identification probability. Mascot and X! Tandem were searched with a fragment ion mass
tolerance of 0.020 daltons and a parent ion tolerance of 10 parts per million.
Carbamidomethylation of cysteine was specified in Mascot and X! Tandem as a fixed
modification. Glu->pyro-Glu of the N-terminus, ammonia-loss of the N-terminus, gln->pyro-Glu
of the N-terminus, oxidation of methionine, and acetylation of the N-terminus were specified in
X! Tandem as variable modifications. Oxidation of methionine and acetylation of the Nterminus were specified as variable modifications as well.
Mass spectrometry processing was done by the Proteomics Core facility of Wayne State
University. The Wayne State University Proteomics Core Facility is supported by the NIH Center
Grants P30 ES06639, P30 CA22453 and P60 DK020572.

2.9 Parkin Overexpression
Parkin was overexpressed in the rat striatum using the adeno-associated viral vector
(AAV2/6). The rat parkin-coding (AAV2/6-parkin) and the non-coding vector (AAV2/6) were
obtained from Dr. Bernard Schneider from the Swiss Federal Institute of Technology (EPFL),
Lausanne, Switzerland. Virus-loaded dose of the vector (2x107 transducing units, TUs) in 2 µl
volume were injected in the brain as per Liu et al (Liu, Traini et al. 2013). Briefly, rats were
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allowed to acclimitaze for one week and then the parkin-coding or empty vector (2x107 TUs)
was microinjected in the SNPc on the left side of the brain using a stereotaxic apparatus. For
the stereotaxic surgery, mixture of xylazine (20 mg/ml) and ketamine (100 mg/ml) was given
intraperitoneally to anesthetize the rats. Unilateral microinjection was performed on the left
side of brain in the SNPc with either the parkin-coding or non-coding AAV vector. The right side
of the brain for each rat would act as a control for the injected side (left). The microinjection
was done using the following coordinates: − 5.6 mm (AP) from Bregma, − 2 mm (ML) from
Bregma, − 7.6 mm (V) from the dura according to the Paxinos and Watson's rat brain atlas.
Vector (coding or non-coding) was injected at a rate of 0.15 μl/min using a syringe pump with a
5 μl Hamilton syringe (Harvard Apparatus, Holliston, MA, USA). The syringe was left in place for
5 min at − 7.6 mm than withdrawn to − 6.6 mm (5 min) and then − 5.5 mm (for 5 min). The
syringe was slowly raised out of the brain over 2 min.
Three weeks following the microinjections, the rats were divided into 2 groups. One group
was treated with binge METH (4x8 mg/kg, every 2 h, i.p.) and the other group was treated with
saline (4x1 mg/ml, every 2 h, i.p.). Core body temperature was measured before the treatment
and 1 h after each dose of METH or saline. After the drug or saline treatment, rats were
euthanized 1 h following the last dose. After euthanasia, striata were harvested by brain
dissection and were stored at -800C till further analysis.
For assessing the immunoreactivity, both the left (injected side) and the right (non-injected
side) of the striatum were processed independently by density centrifugation as described in
section 2.3 to obtain the total, membrane and cytosol synaptosomal fractions. All the samples
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were maintained on ice at all times. The appropriate fractions were analyzed by western
blotting (as per section 2.4) using antibodies against parkin, CDCrel-1 and VMAT2.

2.10 Chromatography:
Dopamine (DA) Content: Synaptosomal membrane pellet was obtained as per method
described by Chu et al (Chu, Hadlock et al. 2010). Briefly, striatal tissue was homogenized using
a dounce homogenizer (13 strokes) in 0.32M sucrose solution. The homogenate was then
fractionated at 800xg for 24 min at 40C to obtain the supernatant S1. The supernatant S1 was
further fractionated at 22,000xg for 17 min at 40C to obtain the synaptosomal pellet. The pellet
was resuspended in 75 ul of water and osmolarity was immediately restored by adding equal
volume of pH 7.5 buffer containing 25mM HEPES and 100mM potassium tartarate. The
resulting solution was fractionated at 22,000xg for 17 min at 40C to obtain membrane pellet
and cytosolic fraction. The membrane pellet obtained was re-suspended in perchloric acid (final
concentration 0.3N). The resulting solution was then centrifuged at 22,000xg for 30 min to
obtain the precipitated protein pellet. The supernatent was analyzed for DA content using High
Performance Liquid Chromatography (HPLC). The protein pellet was resuspended in 1 N sodium
hydroxide and its concentration was determined using the bicinchoninic acid (BCA) assay. The
DA content obtained by HPLC was normalized per protein precipitated from that particular
sample.

2.11 Statistical Analysis:
Data analysis was performed using GraphPad Prism program (GraphPad Software
Inc.,San Diego, CA, USA). Data with two treatment groups were analyzed using two-tailed,
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unpaired Student's t-test. Data from more than two treatment groups were analyzed using oneway ANOVA. Correlations between immunoreactivities, temperatures and different parameters
was done using Pearson’s correlation test. All data are expressed as mean ± standard errors of
mean (SEM). Significance was set at p<0.05 (95% confidence interval).
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CHAPTER 3 RESULTS
3.1 Establishing the validity of loading controls:
Loading controls are used to account for the uneven loading of gels during
electrophoresis and to normalize bands per loading control. Mostly, cytoskeletal proteins like
actin or tubulin are used as loading controls due to their high abundance in cells. However,
METH is known to affect the levels of actin and tubulins (Maeno, Iwasaa et al. 2000). Therefore,
we decided to assess if the effect of METH on the levels of two cytoskeletal proteins- actin and
alpha-tubulin.

3.1.1 Actin as a loading control
In order to validate actin as a loading control, we assessed the immunoreactivity of actin
across fractions of striatal synaptosomes at 1 h and 24 h after treatment with METH. We found
that binge METH decreased actin immunoreactivity in all 3 fractions: total (-13%), membraneendosomal (-14%) and vesicle-cytosolic (-21%) fractions, at 1 h after the last dose (Student’s ttest, p<0.05). At 24 h, the levels of actin returned to the control levels across all fractions. All
the immunoreactivities were normalized to total protein levels determined by Ponceau S
staining.

47

Actin

Actin/PonS

2.0

SAL
METH

1.5

*

1.0

**

**

0.5

h
24

h
V

24
M

24

h

h
T

V

1

h
1
M

T

1

h

0.0

(A)

(B)

Figure 3.1 Immunoreactivity of striatal actin in the total (T), membrane (M) and
vesicular (V) synaptosomal fractions. (A) The immunoreactivity of actin decreased
across all synaptosomal fractions at 1 h after the binge regimen. At 24 h, these
decreases reversed and the immunoreactivity was restored to normal levels (n=6-7
rats per group). (B) Representative western blot images for actin immunoreactivity at
1 h and 24 h time points. Abbreviations: SAL-saline, METH-methamphetamine, T-total
fraction, M-membrane fraction, V-vesicular fraction, PonS-Ponceau S.

3.1.2 Alpha-tubulin as a loading control
Alpha-tubulin is another cytoskeletal protein that is widely used as a loading control. It is
also a substrate of E3 ligase parkin. To determine if METH affects its levels, we assessed its
immunoreactivity in synaptosomal fractions using electrophoresis and western blotting. The
immunoreactivity of alpha-tubulin showed a statistical trend for an increase in the total
synaptosomal fraction at 1 h (20%, Student’s t test, p=0.0561). At 24 h, a trend to increase was
observed in the membrane fraction (7%, Student’s t test, p=0.0621).
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Figure 3.2 Immunoreactivity of striatal alpha-tubulin in the total (T), membrane (M)
and vesicular (V) synaptosomal fractions (A) At 1 h after the last dose of METH, the
immunoreactivity of alpha tubulin showed a trend for an increase in the total
synaptosomal fraction. At 24 h, it showed a trend for increase in the membrane
fraction, n=6-9 rats per group). (B) Representative western blot images of alphatubulin immunoreactivity at 1 h and 24 h time point. Abbreviations: SAL saline;
METH methamphetamine, T-total fraction, M-membrane fraction, V-vesicular
fraction, PonS-Ponceau S.

3.2 Validation of METH neurotoxicity:
In experimental animals, high doses of METH are known to cause hyperthermia, which is
one of the factors mediating the neurotoxicity of the drug. Increased core body temperature
after METH increases toxicity and lower body temperature protects against METH-induced
toxicity (Bowyer, Davies et al. 1994, Yamamoto, Moszczynska et al. 2010). In order to confirm
that METH induces hyperthermia in our model, core body temperature was measured
throughout the METH treatment. Rectal temperature was measured before the start of the
treatment and one hour following each dose of METH or saline. As seen in Figure 3.3, significant
hyperthermia at each measurement throughout the treatment was observed in animals in the 1
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h and 24 h time point groups (two-way ANOVA with repeated measures, 1 h, p<0.01, F=12.25,
dfn=4, dfd=80; 24 h, p<0.01,F=7.10, dfn=4, dfd=40).

METH-induced hyperthermia in animals
euthanized at 1 h after treatment
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Figure 3.3 Hyperthermia during METH-treatment. We observed a significant increase in
rat core body temperatures in both sacrifice groups 1 h (n=11) (A) and 24 h (n=6) (B) after
binge METH. Abbreviations: SAL-saline; METH-methamphetamine.

3.3 The effect of binge METH on trafficking of Vesicular Monoamine Transporter 2
(VMAT2) in DAergic terminals:
Previous studies have reported changes in striatal VMAT2 immunoreactivity after high
dose METH at 1 h and 24 h following the treatment. Changes in partially glycosylated VMAT2
(~55 kDa) in the membrane and vesicular synaptosomal fractions were observed at 1 h time
point (Riddle, Topham et al. 2002, Ugarte, Rau et al. 2003). A decrease in glycosylated VMAT2
(~68 kDa) in vesicular fraction at 1 h and decreases across all synaptosomal fractions at 24
hours has also been shown (Eyerman and Yamamoto 2005, Eyerman and Yamamoto 2007).
To determine whether trafficking of VMAT2 is impaired in our neurotoxicity model, we
assessed immunoreactivity of VMAT2 in synaptosomal fractions at 1 h and 24 h after binge
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METH. Of the 3 isoforms of VMAT2, the partially glycosylated form (55 kDa) and the
glycosylated form (75 kDa) were identified by our antibody. The unglycosylated VMAT2 (45
kDa) was detected at very low levels in terminal endings. As compared to saline controls, no
change was observed in the immunoreactivity of VMAT2 at 1 h time point. Trend for a decrease
in the immunoreactivity of both isoforms of VMAT2 in the cytosolic fraction was seen at 24 h
time point (-20%, Student’s t test, p=0.0666). In our fractionation protocol, we did not spun
down vesicles to concentrate the sample. As a result of this, we observed a weaker signal for
VMAT2 in cytosolic fraction as compared to other fractions in the western blot image. We
expected a decrease in VMAT2 at 1 h due to the activation of DA D2 receptors (Truong,
Newman et al. 2004) by METH-released DA.
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Figure 3.4 Immunoreactivity of striatal VMAT2 (55 kDa and 75 kDa species) in the
total (T), membrane (M) and vesicular (V) synaptosomal fractions (A) No differences
in the immunoreactivity of VMAT2 were observed in any fractions at 1 h time point.
At 24 h, a tendency for a decrease in the cytosolic fraction was observed (n=6-9). (B)
Representative western blot images for VMAT2 immunoreactivity at 1 h and 24 h
after binge METH. Abbreviations: SAL-saline; METH-methamphetamine, T-total
fraction, M-membrane fraction, V-vesicular fraction, PonS-Ponceau S.
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3.4 The effect of binge METH on the levels of parkin:
3.4.1 Parkin in striatal synaptosomes:
Binge METH (4x10 mg/kg, every 2 h, i.p.) decreases the levels of E3 ligase parkin in
striatal synaptosomes by DA-mediated oxidative damage (Moszczynska and Yamamoto 2011).
To evaluate the effect of METH on the E3 ligase parkin in our model of METH neurotoxicity (4x8
mg/kg, every 2 h, i.p.), we assessed immunoreactivity of parkin at 1 h and 24 h after binge
METH. As assessed by western blotting, the immunoreactivity of parkin in the total
synaptosomal fraction showed a statistical trend for a decrease at 1 h after the last dose of
METH (-19%, Student’s t test, p=0.0629, n=8-12 rats per group). No statistically significant
changes were observed in any other fractions at 1 h. The Figure 3.5 shows 2 subpopulations of
rats in the membrane (p=0.44) and vesicular fraction (p=0.10) as well. These decreases might
become statistically significant if sample sizes are increased. The immunoreactivity remained
unchanged across all fractions at 24 h time point. The small deficit observed in the
immunoreactivity of parkin could have been a result of two subpopulations of rats, which
showed different effects. As can be seen in the scatter dot plot, one subpopulation of rats
shows deficit in parkin whereas the other subpopulation shows no change in the levels of
parkin following METH (Figure 3.5 A). Since the rats used in this study are outbred rats, the
variability in effect observed could be due to individual differences between the rats.
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Figure 3.5 Parkin levels in the total (T), membrane (M) and vesicular (V) synaptosomal
fractions at 1 h and 24 h time points. (A) A trend for a decrease in parkin was
observed in total fraction at 1 h (n=8-12). However, 2 subgroups of rats were
observed, one with a decrease and the other with no change in parkin
immunoreactivity. At 24 h time point, no change was observed across all fractions. (B)
Representative western blot image of parkin from rat showing decrease at 1 h and 24
h time point. Abbreviations: SAL-saline; METH-methamphetamine, T-total fraction, Mmembrane fraction, V-vesicular fraction, PonS-Ponceau S.
3.4.2 Parkin monomers and oligomers:
METH releases DA and free DA is known to covalently modify parkin, causing it to
aggregate. These aggregates of parkin lack their usual E3 ligase function (LaVoie, Ostaszewski et
al. 2005). Since the deficit in parkin observed under our conditions was small and occurred only
in a subpopulation of rats, we decided to assess whether there was an increase in the levels of
parkin aggregates accompanied by a decrease in monomeric form, without a change in the total
levels of parkin. To determine this, we performed electrophoresis under non-reducing
conditions to prevent the aggregates from breaking down. This was followed by western
blotting using the parkin antibody. Parkin aggregates are usually observed as tetramers around
200 kDa as observed by previous studies (LaVoie, Ostaszewski et al. 2005). We did not observe
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any such high molecular weight aggregates of parkin. However, our antibody detected a
complexed form of parkin around 110 kDa. This form has been found by another study, which
suggested that the 110 kDa form is a protein complex where parkin occurs bound to other
interacting proteins. This study also found that the levels of this 110 kDa form do not change
with the change in the expression of parkin (VanHumbeeck, Waelkens et al. 2008). This explains
our finding that there is no change in the levels of the complexed form of parkin (110 kDa) after
METH, as compared to saline.
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Figure 3.6 Parkin levels after METH under non-reducing conditions (A) No change was
observed in the monomeric form (52 kDa band) at 1 h time point. (B) METH did not
cause any change in the levels of parkin complex (~110 kDa) in either total or
membrane synaptosomal fraction. (C) Representative western blot image of
monomeric and complexed form of parkin at 1 h after METH. Abbreviations: SAL-saline;
METH-methamphetamine, T-total fraction, M-membrane fraction, PonS-Ponceau S.

54

3.4.3 Parkin in DAergic terminals:
DAergic terminals constitute ~21% of the total nerve terminals in the striatum. This
suggests that even if there was a deficit in parkin in these terminals, we would not see it by
western blotting due to dilution of the effect. To determine whether there was any decrease in
parkin in DAergic terminals, we performed immunoflorescence on striatal synaptosomes plated
on microscopic slides and double labeled with antibodies against parkin and the
catecholaminergic marker TH.
To ensure unbiased results, all the slides were numbered and the person taking the
images was blinded i.e. the identity of slides was kept unknown until the final analysis of
colocalization. Multiple areas were imaged per slide. The Leica software calculated Pearson’s
coefficient for colocalization in each area and these values were normalized per TH intensity for
that area. The normalized values were averaged per animal and statistical analysis was
performed using Student’s t-test. No statistically significant changes were observed between
saline and METH treated brains. (SAL, 0.005 + 0.0007 N=4; METH, 0.004 + 0.0005, N=4;
Student’s t test, p=0.5136).
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Figure 3.7 No change was observed in parkin-TH double staining as assessed by
immunoflorescence under confocal microscope. As compared to (A) SAL treated
samples, the immunoreactivity remained unchanged in (B) METH treated samples (redparkin; green-TH) (a) green channel for TH (b) red channel for parkin (c) overlay (d)
scatter plot for colocalization.
3.4.4 Parkin in cerebellar synaptosomes:
Cerebellum has negligible DA content. To determine whether the trend for decrease in
parkin in total fraction observed previously was specific to DA-rich striatal synaptosomes, we
assessed the immunoreactivity of parkin in total and membrane fraction of synaptosomes from
cerebellum harvested at 1 h after the last dose of METH. As compared to saline controls, an
increase in parkin immunoreactivity was observed in total (37%, Student’s t-test, p<0.05) and
membrane (31%, Student’s t-test, p<0.05) fractions.
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Figure 3.8 Parkin in the total (T) and membrane (M) synaptosomal fractions in cerebellum. (A)
An increase in parkin in total and membrane fractions was observed at 1 h after binge METH
(n=5). (B) Representative image for parkin in cerebellum at 1 h after binge METH.
Abbreviations: SAL-saline; METH-methamphetamine, T-total fraction, M-membrane fraction,
PonS-Ponceau S.

3.5 The effect of binge METH on the levels of CDCrel-1:
Excess of CDCrel-1 damages DAergic neurons in rodents (Zhizhong Dong 2003). CDCrel-1
is a substrate of parkin (Yi Zhang 2000). Consequently, a deficit in parkin levels or its function
can result in increased CDCrel-1 levels. Therefore, we next assessed the levels of CDCrel-1
protein in synaptosomal fractions at 1 h and 24 h after METH.

3.5.1 CDCrel-1 in striatal synaptosomes
Using western blotting, we observed that in a subpopulation of rats, METH caused a
trend for increased immunoreactivity of CDCrel-1 in total synaptosomal fraction at 1 h after
binge regimen (35%, Student’s t test, p=0.0542). Also, a trend for a decrease was observed in
the cytosolic fraction at 24 h time point (-15%, Student’s t test, p=0.0698). As with parkin, we
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observed two subpopulations of rats, one with an increase in the immunoreactivity of CDCrel-1
and the other with no change after binge METH (Figure 3.9 A).
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Figure 3.9 CDCrel-1 levels in total (T), membrane (M) and vesicular (V) synaptosomal
fractions. (A) A trend for an increase in immunoreactivity of CDCrel-1 was observed in the
total fraction at 1 h (n=10). 2 subgroups of rats were observed, one with an increase and the
other with no change in immunoreactivity. At 24 h, CDCrel-1 showed a trend for a decrease
in the cytosolic fraction. (B) Representative blots for CDCrel-1 at 1 h and 24 h time points.
Abbreviations: SAL-saline; METH-methamphetamine, T-total fraction, M-membrane
fraction, V-vesicular fraction, PonS-Ponceau S.

3.5.2 CDCrel-1 in cerebellar synaptosomes:
As cerebellum has minimal DAergic innervations, the levels of CDCrel-1 in the cerebellum
were assessed to determine whether METH affects other non-DAergic nerve terminals there.
Unlike striatum, the synaptosomes from cerebellum show no increase in the immunoreactivity of
CDCrel-1 after binge METH. This serves as a negative control to the effect observed in striatal
synaptosomes.
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Figure 3.10 Immunoreactivity of cerebellar CDCrel-1 in the total (T) and membrane (M)
synaptosomal fractions (A) No change was observed in the immunoreactivity of CDCrel-1 in
total or membrane fractions of cerebellar synaptosomes at 1 h after binge METH (n=6). (B)
Representative blot of CDCrel-1 in cerebellum at 1 h time point. Abbreviations: SAL-saline;
METH-methamphetamine, T-total fraction, M-membrane fraction, PonS-Ponceau S.

3.6 Parkin CDCrel-1 protein-protein interactions:
CDCrel-1 is known to be a substrate of parkin in vitro (Yi Zhang 2000). To determine
whether the two proteins interact with each other under our in vivo conditions and whether
this interaction is affected by METH treatment, we performed correlation analyses and
coimmunoprecipitation studies.

3.6.1 Correlation analyses:
As described previously, we assessed immunoreactivity of both parkin and CDCrel-1 in
striatal synaptosomes from rats killed 1 h after METH or saline. Although CDCrel-1 is a substrate
of parkin, we did not know whether changes in their levels are dependent on each other under
our treatment conditions. To determine this, we correlated the immunoreactivity of parkin and
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CDCrel-1 from saline- as well as METH-treated rats. We observed a trend for a correlation
between the two proteins in saline-treated rats (36%, Pearson’s correlation analysis, p=0.0830,
r2=0.3686), which decreased after the treatment with METH (2.32%, p=0.6547, r2=0.02322).
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Figure 3.11 Correlation analyses between parkin and CDCrel-1 (A) A trend for correlation
between parkin and CDCrel-1 was observed in saline (SAL) rats (36%) (B) This trend for
correlation between the two proteins was lost after METH treatment.
3.6.2 Coimmunoprecipitation:
To establish the interaction between parkin and CDCrel-1 in rat striatum, we employed
coimmunoprecipitation technique. Striatal synaptosomes from saline- and METH-treated rats
were subjected to coimmunoprecipitation using antibodies against CDCrel-1 and parkin. First,
we set to determine in an untreated brain whether the two proteins coimmunoprecipitate with
each other. After this, we compared the immunoprecipitation between saline and METH
treatment conditions (Figure 3.13 A). We detected a decreased interaction between the two
proteins after METH (Figure 3.13 B).
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(A)

(B)

Figure 3.12 Coimmunoprecipitation analyses between parkin and CDCrel-1. (A) Parkin
coimmunoprecipitated with CDCrel-1 in untreated striatal synaptosomes as a qualitative
confirmation of the fact that the two interact in vivo (n=1). (B) Moreover, we observed
that the interaction between parkin and CDCrel-1 decreased after METH (n=3). Tissue
lysate was used as positive control and beads+tissue sample was used as negative control.
Abbreviations: SAL-saline; METH-methamphetamine, WB-western blotting, IPimmunoprecipitation, Prk-parkin.

3.7 Correlation between parkin, CDCrel-1, VMAT2 and hyperthermia
Hyperthermia plays an important role in the toxicity of METH. Moreover, increased
toxicity of METH is observed with increased core body temperatures (Bowyer, Davies et al.
1994). To determine whether the changes in immunoreactivity of parkin, CDCrel-1 and VMAT2
after METH are dependent on hyperthermia, we correlated their immunoreactivities to core
body temperature of rats. We found that hyperthermia has no effect on the immunoreactivity
of CDCrel-1 (-2.5%, Pearson’s correlation analysis, p=0.6397, r2=0.025) or VMAT2 (0.2%,
Pearson’s correlation analysis, p=0.8862, r2=0.002). Hyperthermia had some effect on the
immunoreactivity of parkin (20%, Pearson’s correlation analysis, r2=0.2074), however the
correlation was not statistically significant (p=0.1592).
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Figure 3.13 To determine whether hyperthermia
plays a role in altering protein levels, we
correlated core body temperature to the
respective immunoreactivities of parkin, CDCrel1 and VMAT2. Correlation analyses showed a
lack of statistically significant correlations
between hyperthermia and immunoreactivity of
parkin, CDCrel-1 and VMAT2 in rat striatal
synaptosomes.

(C)

3.8 CDCrel-1 VMAT2 protein-protein interactions:
We hypothesized that the increased CDCrel-1 after METH entraps VMAT2 at the
membrane of the nerve terminal. To assess whether CDCrel-1 interacts with VMAT2, we
performed correlation, communoprecipitation and mass spectrometry studies in synaptosomes
from saline as well as METH treated rats.

3.8.1 Correlation analyses
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Using SDS-PAGE and western blotting, we determined the immunoreactivity of CDCrel-1
and VMAT2 in the synaptosomal membrane fraction after saline and METH treatment. We then
plotted the immunoreactivity of both these proteins to perform a correlation study. We
observed that there was no correlation between the two proteins in saline treated rats.
However, after METH treatment, there was a statistical trend for a correlation between CDCrel1 and VMAT2 (40%, Pearson’s correlation analysis, r2=0.3991, p=0.0680).
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Figure 3.14 Correlation analyses between CDCrel-1 and VMAT2 immunoreactivities in
striatal synaptosomes (membrane fractions) from rats killed 1 h after binge METH (4x8
mg/kg, every 2 h, i.p.). No correlation was observed between CDCrel-1 and VMAT2 in
control rats. However, after METH, a trend for correlation between the two proteins was
observed (40%) (n=9). Abbreviations: SAL-saline; METH-methamphetamine.
3.8.2 Coimmunoprecipitation
In order to establish their interaction, we performed coimmunoprecipitation of VMAT2
and CDCrel-1 in the membrane fraction of synaptosomes. First, we assessed whether CDCrel-1
coprecipitates with VMAT2 under basal conditions in untreated rat striatal total syanptosomes
(Figure 3.16 A). Thereafter, we performed immunoprecipitation to compare the interactions of
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the two proteins under saline and METH treatment in the membrane fraction of synaptosomes.
Concurrent with the correlation analysis, we observed that there was more interaction
between VMAT2 and CDCrel-1 after METH as compared to saline in one rat (Figure 3.16 B) but
not all three rats (Figure 3.16 D).The validation of coimmunoprecipitation was done using
proper controls such as IgG to specific antibody species and unconjugated beads incubated with
the sample (Figure 3.16 C).

(A)

(B)

(C)

(D)

Figure 3.15 Coimmunoprecipitation analysis of VMAT2-CDCrel-1 in (A) control rat striatal
synaptosomes (B) More VMAT2 coimmunoprecipitated with CDCrel-1 after METH as
compared to saline in one rat out of 3. (C) Controls for coimmunoprecipitation (D)
Representative image of rat not showing increased coimmunoprecipitation of VMAT2 and
CDCrel-1 after METH. Abbreviations: SAL-saline; METH-methamphetamine.
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3.8.3 Mass Spectroscopy
To

validate

the

interaction

between

VMAT2

and

CDCrel-1

observed

by

coimmunoprecipitation, we employed the mass spectrometry technique. In this method,
magnetic beads conjugated to the VMAT2 antibody were incubated with the membrane
fraction of the synaptosomal preparation to pool VMAT2 from the sample. This experiment was
carried out in synaptosomal preparations from both saline- and METH-treated rats. To detect
the proteins that coimmunoprecipitated with the pooled VMAT2, the eluent from the beads
was run on a gel and subjected to mass spectroscopy analysis. Along with many other
exocytotic proteins, we observed that the protein Septin 5 (CDCrel-1) coimmunoprecipitated
with VMAT2 in both samples, saline and METH. No statistically significant differences were
observed in the amount of VMAT2 protein that coimmunoprecipitated in METH-treated rats as
compared to saline controls. However, we observed increase in the amount of CDCrel-1
coprecipitated with VMAT2 in one rat as compared to the other two. This variable effect seen
could be due to individual differences between these outbred rats. The coimmunoprecipitation
of the pre-synaptic marker protein bassoon indicates the abundance of pre-synaptic
synaptosomes in our sample. Due to the hydrophobic nature and low abundance of VMAT2, it
was not detected in the initial run. To validate our method and ensure that VMAT2 was pooled
by the beads, we repeated the experiment using double quantity of beads. This subsequent
experiment led to detection of VMAT2 by mass spectrometry.
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3.9 High Performance Liquid Chromatography (HPLC):
To determine to what extent METH causes depletion of DA in striatum, DA content was
assessed in membrane fraction of synaptosomes using HPLC. There was a significant decrease
in the levels of DA at both time points, 1 h and 24 h after binge METH (Figure 3.17 A). Although
the levels of DA at both 1 h and 24 h were depleted, no change in the levels of the protein
VMAT2, which is an integral part of DA storage vesicles, was observed at the membrane of the
nerve terminal (Figure 3.17 B). This implies that there is no physical loss of vesicles at the
membrane. The loss in DA could be a result of functional impairment of the DA sequestering
vesicles despite a lack of change in their levels.
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Figure 3.16 DA content in the storage vesicles at the membrane assessed by HPLC (A) As
compared to saline controls, a significant decrease in DA levels was observed in these vesicles at
both the time points, 1 h and 24 h after the last dose of binge METH. Although depletion of DA
was observed at both time points, (B) no change in the levels of VMAT2 was observed in the
membrane fraction at either 1 h or 24 h time point.

3.10 Influence of parkin on trafficking of VMAT2:
Parkin is known to play a protective role in several neurodegenerative diseases as an E3
ligase (Wilhelmus, Nijland et al. 2012). Also, parkin protect DAergic terminals of the striatum
from the toxic effects of METH (Liu, Traini et al. 2013). To determine whether overexpression of
parkin reverses the accumulation of its substrate CDCrel-1 and impaired trafficking of VMAT2,
we assessed immunoreactivity of these proteins by western blotting in rat brain overexpressing
parkin in the nigrostriatal DA system on the left side of the brain.

3.10.1 Establishing the overexpression of parkin:
Parkin-coding adeno associated viral vector (AAV) was microinjected in the left SNPc of
rat brain. Control group of rats were microinjected with non-coding AAV. The immunoreactivity
of parkin was evaluated in the striatum after 3 weeks. To study the effect of binge METH (4x8
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mg/kg) on parkin overexpressing rats, rats were treated with either saline or METH (4x8 mg/kg)
and killed 1 h after the last dose.
Western blot analysis revealed that there was a significant overexpression of parkin in
the striatum 3 weeks after the microinjection (5 fold increase) (one-way ANOVA, p<0.05, F
value 24.18, r2=0.8580). Bonferroni’s multiple comparision (post-hoc) test revealed significant
increase in the level of coding vector injected rats vs. wild type rats. Two-way ANOVA would
have been more appropriate for this data, but small sample size and unequal number of
subjects in each group did not allow us to use two-way ANOVA. Since t-test would not be
appropriate considering we are comparing more than two groups, we decided to use one-way
ANOVA for our analysis.
We observed a 23% (p=0.029) and 30% (p=0.3932, not statistically significant by t test)
decrease in parkin levels in METH-treated rats as compared to saline controls in WT and noncoding vector microinjected rats respectively. This is consistent with our previous results in wild
type animals as described in section 3.4.1. No change was observed in the parkin levels
between WT rats and rats injected with non-coding vector, suggesting that the vector alone
does not affect the levels of parkin. Moreover, the levels of parkin in METH-treated parkin-AAV
injected rats were much lower than that of saline-treated parkin-AAV injected rats (35%
decrease). This suggests that 4x8 mg/kg METH causes decrease in levels of parkin in the
striatum.
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Figure 3.17 (A) Parkin overexpression by the AAV vector; 5 fold increase in the levels of parkin was
observed. METH decreased the levels of parkin even in rats overexpressing parkin (-35%). No
change was observed in parkin levels between WT and rats injected with non-coding vector. (B)
Representative blot of parkin in total synaptosomes at 1 h time point. Abbreviations: WT SAL=Wild
type saline (WS); WT METH=Wild type methamphetamine (WM); SAL AAV=Saline treatment in rat
injected with non-coding vector (S-NC); METH AAV=METH treatment in rat injected with noncoding vector (M-NC); SAL-AAV-parkin=saline treatment in rat injected with parkin-coding vector
(S-C); METH-AAV-parkin=METH treatment in rat injected with parkin-coding vector (M-C).

3.10.2 Effect of parkin overexpression on CDCrel-1 levels:
We found a trend for an increase in the levels of CDCrel-1 in total fraction of
synaptosomes in wild type rats. To determine whether overexpression of parkin led to a
decrease in CDCrel-1 levels, we assessed immunoreactivity of CDCrel-1 in the total and
membrane fraction of synaptosomes. As described previously, data is divided based on 6
treatment groups. Contrary to our expectation, no statistically significant changes were
observed in the immunoreactivity of CDCrel-1 in either total (one way ANOVA, p=0.8992, F
value= 0.3132, r2=0.0726) or membrane fraction (one way ANOVA, p=0.9559, F value= 0.2064,
r2=0.0490) of synaptosomes after overexpression of parkin (n=3-5). No change was observed in
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total fraction between the WT and rats injected with non-coding vector. Thus, the vector does
not affect the levels of CDCrel-1. As compared to SAL-AAV-parkin group, CDCrel-1 levels did not
change following METH administration (METH-AAV-parkin rats) in total or membrane fraction.
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Figure 3.18 (A) METH did not change CDCrel-1 levels in WT or overexpressing rats. (B)
Representative blot of CDCrel-1 in total synaptosomes at 1 h. (C) No change was observed in
CDCrel-1 after overexpressing or WT vs. non-coding vector injected groups (membrane fraction)
(D) Representative blot of CDCrel-1 in membrane fraction at 1 h (n=3-5) Abbreviations: WT SAL=Wild type saline (WS); WT METH=Wild type methamphetamine (WM); SAL AAV=saline treatment
in rat injected with non-coding vector (S-NC); METH AAV=METH treatment in rat injected with
non-coding vector (M-NC); SAL-AAV-parkin=saline treatment in rat injected with parkin-coding
vector (S-C); METH-AAV-parkin=METH treatment in rat injected with parkin-coding vector (M-C).
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3.10.3 Effect of parkin overexpression on VMAT2 levels and trafficking:
The main aim of the parkin overexpression study was to determine whether parkin plays
a role in protecting against the impaired trafficking of VMAT2 caused by METH (Riddle, Topham
et al. 2002, Ugarte, Rau et al. 2003). Parkin was overexpressed in rats using the AAV gene
transfer vector. The levels of VMAT2 were assessed across all three fractions of synaptosomes
(total, membrane and cytosolic). One-way ANOVA with Bonferroni’s multiple comparision test
was used to compare the VMAT2 levels amongst multiple groups. No statistically significant
changes were observed in the total (one-way ANOVA, p=0.8454, F value=0.3965, r2=0.0901);
membrane (one way ANOVA, p=0.7546, F value=0.5250, r2=0.1160) or cytosolic fraction (one
way ANOVA, p=0.5785, F value=0.7759, r2=0.1625). Across all fractions, no differences in levels
of VMAT2 following METH treatment were observed in either METH-AAV-parkin vs. SAL-AAVparkin or METH-AAV vs. SAL-AAV. We assessed the levels of parkin only in total synaptosomal
fractions to validate whether the overexpression of parkin was successful.
The results obtained from this parkin overexpression study suggest that parkin does not
play a role in the trafficking of VMAT2. However, we accept the drawback of our study, which is
a small number of subjects per group. Thus, we might observe different results after adding
more rats to the study.

(E)

A

A

A

A
V

TH

E

A
A
V
V
M
E
p
ar
TH
ki
A
n
A
V
-p
ar
ki
n

A
L

S

TH

E

M

A
L

S

M

A
L

S

Normalized cytosolic VMAT2

M
ET
H

SA
L
A

A

A
V

A
V
Vpa
rk
in
A
A
Vpa
rk
in

ET
H

A

A

M

SA
L

ET
H

M

SA
L

Normalized membrane VMAT2

M
ET
H

SA
L

A

A

A
V

ET
H

A
V
Vpa
rk
in
A
A
Vpa
rk
in
A

A

ET
H

M

SA
L

M

SA
L

Normalized total VMAT2

71

1.5

Total VMAT2 in PO rats

1.0

0.5

0.0

(A)
(B)

1.5

Membr VMAT2 in PO rats

1.0

0.5

0.0

(C)
(D)

1.5

Cytosolic VMAT2 in PO rats

1.0

0.5

0.0

(F)

72

Figure 3.19 The immunoreactivity of VMAT2 (55 kDa and 70 kDa) in total (A), membrane (C) and
vesicular (E) synaptosomes at 1 h after binge METH was not different from the wild type rats (n=35). Representative blot of VMAT2 in total (B), membrane (D) and vesicular fraction (F) of
synaptosomes at 1 h time point. As compared to saline, a 30% decrease (not statistically
significant) in WT METH-treated group was observed in the cytosolic fraction. Abbreviations: WT
SAL=Wild type saline (WS); WT METH=Wild type methamphetamine (WM); SAL AAV=saline
treatment in rat injected with non-coding vector (S-NC); METH AAV=METH treatment in rat
injected with non-coding vector (M-NC); SAL-AAV-parkin=saline treatment in rat injected with
parkin-coding vector (S-C); METH-AAV-parkin=METH treatment in rat injected with parkin-coding
vector (M-C).
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Chapter 4 Discussion
4.1 Loading controls:
Microtubule dynamics play a role in many of the active processes in the brain. It has
been shown that actin polymerization is responsible for METH associated memory (the memory
responsible for relapse to drug usage); and its depolymerization causes disruption of this
memory in self administering rats and mice (Young, Aceti et al. 2014). Previous study in mice
showed up-regulation of G-actin and F-actin proteins after chronic METH administration
(Shibasaki, Mizuno et al. 2011). This study demonstrated that actin dynamics is very responsive
to METH administration. Another study on levels of tubulins after single as well as chronic
injections of METH, found no change in the expression of alpha tubulin mRNA. A single dose of
METH was shown to induce the rearrangement of neuronal network with increased length and
density of dendritic spines (Ujike, Takaki et al. 2006). This rearrangement is brought about by
cytoskeletal protein dynamics. Moreover, METH disrupts blood brain barrier (BBB) by
mobilization of tight junction protein occludin from plasma membrane to endosomes. One
study has shown that this disruption of BBB can be prevented by inhibition of actin nucleation
(Park, Kim et al. 2013). The above literature suggests that actin and cytoskeletal rearrangement
play an important role in the effects produced by METH. Actin and alpha tubulin are widely
used loading controls. Based on the above mentioned literature on effect of METH on
cytoskeletal proteins (Shibasaki, Mizuno et al. 2011, Young, Aceti et al. 2014) as well
unpublished results from Dr. Moszczynska’s unpublished results on levels of alpha-tubulin after
METH, we decided to assess its effect on actin and alpha-tubulin in our model. Consistent with
previous findings, we observed a change in levels of actin and tubulin after METH treatment. At
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1 h time point, we observed a significant decrease in actin immunoreactivity across all
synaptosomal fractions. The levels of alpha tubulin in total synaptosomes had a trend for an
increase at 1 h.

4.2 Binge METH neurotoxicity:
Binge regimen of METH means repeated administration of the drug at regular intervals
of time. Several models of binge METH regimen have been studied and all produce different
intensity of toxicity. A dose of 4x5 mg/kg in rats produced ~27% loss of striatal DA 7 days after
the treatment (Fornai, Torracca et al. 1996). This decrease was even more severe (80% DA loss,
70% loss of DOPAC, 60% loss of HVA) 3 days after the treatment of mice with 4x5 mg/kg dose
(Boireau, Bordier et al. 1995). Hyperthermia produced by this dose was about 38-390C
(Bowyer, Tank et al. 1992). In a different study, administration of 4x15 mg/kg regimen of METH
to mice produced about 75% loss in striatal DA 3 days after the treatment (Green, Souza et al.
1992). In rats, 4x7.5 mg/kg dose produced about 26% depletion of striatal DA (Nash and
Yamamoto 1992) whereas 4x10 mg/kg dose produced a 56% DA depletion in the striatum 7
days after METH (Wallace, Gudelsky et al. 1999). This dose was also found to decrease
immunoreactivity of parkin at 1 h and 24 h after the last dose (Moszczynska and Yamamoto
2011). The 4x10 mg/kg dose produced a hyperthermia of 40-410C as observed by previous
studies (Wallace, Gudelsky et al. 1999, Moszczynska and Yamamoto 2011). Bowyer and
colleagues found a correlation between hyperthermia and METH induced toxicity (Bowyer,
Tank et al. 1992). Our study used 4x8 mg/kg dose and we observed significant hyperthermia in
our rats. Since our dose was lesser than the 4x10 mg/kg regimen, our toxicity profile was not as
severe, on average, as in some other studies, e.g. Moszczynska and Yamamoto’s study, which
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observed about 40% deficit in parkin at 1 h after binge METH. Moreover, we observed a deficit
in parkin in only a subpopulation of rats and not extending beyond the 1 h time point. Thus,
based on the previous literature and hyperthermia as seen in our study, the toxicity in our
model is on a threshold of serious damage caused by METH.

4.3 Impaired trafficking of VMAT2 after binge METH:
The basic function of VMAT2 is to sequester intracellular DA into synaptic vesicles. To
the best of our knowledge, no study so far has published about VMAT2 being internalized to DA
storage vesicles after administration of amphetamines or oxidative stress. So, as far as we
know, VMAT2 remains on the surface of the synaptic vesicle and the levels and localization of
VMAT2 represent the levels and localization of the vesicles in the nerve terminal. Previous
studies have shown that METH alters the levels of VMAT2 and localizes them to a region not
retained in the synaptosomal preparation within 1 h (Riddle, Topham et al. 2002, Ugarte, Rau et
al. 2003). We did not observe this effect in our study. One reason for this could be our lower
METH dose (4x8 mg/kg) as compared to the dose used in these studies (4x10 mg/kg). In terms
of the effect of binge METH on VMAT2 expression at the membrane, one study has shown an
increase whereas the other shown no change in the levels of VMAT2 (~55 kDa) with a decrease
in the cytosolic fraction at 1 h time point (Riddle, Topham et al. 2002, Ugarte, Rau et al. 2003).
These findings suggested impaired trafficking of VMAT2 vesicles to the cytosol. We did not
observe any change in the levels of VMAT2 at the membrane as compared to saline controls.
Our results are similar to those of Riddle and colleagues who observed a lack of change in
VMAT2 at the membrane fraction. Yamamoto group has shown a decrease in the glycosylated
form of VMAT2 (~68 kDa) in the vesicular fraction at 1 h and decreases across all three
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synaptosomal fractions at 24 h time point following METH (Eyerman and Yamamoto 2005). Our
antibody detected both isoforms of VMAT2 and we did not observe any statistically significant
changes in either of the forms in any of the synaptosomal fractions. As mentioned before, one
reason for this discrepancy could be the higher dose used by all the previous studies (4x10
mg/kg). Dose dependency of METH effects has been established with different doses of METH
producing different severity of toxicity (Nash and Yamamoto 1992, Boireau, Bordier et al. 1995,
Wallace, Gudelsky et al. 1999). Another factor that could be a possible contributor to the
different effects observed by us is hyperthermia. Hyperthermia is an important component of
METH toxicity. We observed lower hyperthermia in our rats (39-400C) as compared to the
previous studies (40-410C) (Bowyer, Tank et al. 1992, Eyerman and Yamamoto 2007). Lower
METH dose would have produced less hyperthermia and oxidative damage to proteins,
including VMAT2, resulting in a less impaired trafficking of VMAT2 and its recovery within 24 h
after binge METH.
D2 receptor agonists induce redistribution of VMAT2 vesicles from the plasma
membrane to the cytosol. A single administration of the non selective D2 receptor agonist
quinpirole led to a decrease in the immuonoreactivity of VMAT2 in the membrane with a
corresponding increase in the cytosolic fraction 3 h after the dose (Truong, Newman et al.
2004). Since METH is an indirect D2 agonist by releasing DA in the synapse, we expected to see
redistribution of VMAT2 from membrane to cytosol after METH. However, we did not observe
mobilization of VMAT2 from membrane to cytoplasm. We hypothesized that this lack of
redistribution of VMAT2 could be due to a possible entrapment of VMAT2 at the membrane as
a manifestation of METH toxicity and that it could lead to a dysfunction of VMAT2. This notion
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is supported by a study that found a decrease in vesicular DA uptake at 1 h and 24 h after binge
METH (Brown, Hanson et al. 2000). Thus, VMAT2 could be partially entrapped at the membrane
by CDCrel-1, which is further discussed in the section 4.6.

4.4 Parkin deficit in striatum following binge METH:
The parkin gene and the E3 ligase protein parkin have been widely studied in
Parkinson’s disease (Matsumine, Saito et al. 1997, Hattori, Kitada et al. 1998, Leroy,
Anastasopoulos et al. 1998). Dysfunction and damage to parkin due to METH and oxidative
stress has also been studied in vitro and in vivo (LaVoie, Cortese et al. 2007, Moszczynska and
Yamamoto 2011). Our previous study on rat synaptosomes after binge regimen of METH (4x10
mg/kg) has shown decrease in parkin levels in total synaptosomes as early as 1 h after the last
dose of METH. Parkin levels were still decreased at 24 h but returned to the control levels at 48
h after METH. Our current study, using 4x8 mg/kg METH, found a trend for a decrease (-19%) in
parkin in total synaptosomes at 1 h and no change at 24 h time point. In addition, two
subpopulations of rats were observed in our study at 1 h time point: one with a decrease in
parkin and the other with no change. These two sub groups of rats with different effects led to
the lower overall deficit observed in parkin. We tried to deduce the possible cause for the two
subpopulations of rats in our results. For this, we correlated the immunoreactivity of parkin to
different indices such as core body temperature and immunoreactivity of CDCrel-1. However,
we could not find any specific correlations between the subpopulations of rats and other
indices. We could not determine what led to different levels of decrease in parkin levels in
response to METH insult.
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One of the most obvious parameters that was different between our study and the
previous one was the dose of METH. A number of models for different regimen and dosing of
METH have been studied. Binge regimens such as 4x10 mg/kg every 2 h, 4x7.5 mg/kg every 2 h,
4x5 mg/kg every 2 h have been shown to produce different toxic effects (Imam, el-Yazal et al.
2001, Zhu, Xu et al. 2006, Phillips, Kamens et al. 2008, Good and Radcliffe 2011). A single dose
of METH produced dose-dependent reductions in striatal DA levels: to 71% (at 20 mg/kg), 49%
(at 30 mg/kg) and 29% (at 40 mg/kg) of control levels, 3 days following the treatment with
METH (Fukumuraa, Cappona et al. 1998). Previous studies on binge METH neurotoxicity showed
that a dose of 4x10 mg/kg produced 56% toxicity as observed by DA depletion at 7 days in the
striatum, 4x7.5 mg/kg produced 26%, whereas 4x5 mg/kg produced 27% toxicity (Fornai,
Torracca et al. 1996, Wallace, Gudelsky et al. 1999). Thus, different METH doses produce
different levels of toxicity, which is directly proportional to the dose of METH. More toxicity is
observed at higher dose. This loss of DA content is associated with the increase in DA quinones
production by METH. Oxidative stress caused by METH is one of the major mechanisms of
METH toxicity and the DA ROS produced are known to damage parkin (LaVoie, Ostaszewski et
al. 2005, LaVoie, Cortese et al. 2007, Moszczynska and Yamamoto 2011). Most of the previous
studies on binge METH toxicity have used 10 mg/kg of METH, free-base. Under our conditions,
this dose was found to be very toxic and led to high mortality rates amongst the rats. Due to
this reason, we used 8 mg/kg of free-base METH. This relatively lower dose of 8 mg/kg might be
responsible for the lesser decrease in parkin levels than observed by previous study, which used
4x10 mg/kg regimen (Moszczynska and Yamamoto 2011). Also, at 4x10 mg/kg dose, the effect
of METH on parkin reverses by 48 h; this time might be earlier for the lower METH dose of 4x8
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mg/kg. This could be the reason why we see no effect at the 24 h time point as the effect of
METH would be washed off by that time.
We analyzed multiple possible causes for the discrepancy of our results with the
previously observed deficit in parkin (Moszczynska and Yamamoto 2011) at 1 h and 24 h:
(1)

Hyperthermia: Increase in core body temperature as a result of METH

administration is a common manifestation of METH toxicity. Hyperthermia is known to
augment the toxic effects of METH such as DA depletion (Sandoval, Hanson et al. 2000,
Tata, Raudensky et al. 2007). For example, one study performed an experiment to
observe the toxicity of high dose METH (4x10 mg/kg) in a low temperature environment
(230C) in mice. They observed only 20% decrease in DA as compared to 80% depletion at
room temperature (Ali, Newport et al. 1994). As described previously, the range for
hyperthermia found in most studies is 39-41oC. The core body temperatures of the rats
in the previous study were more towards the upper limit of the range (40-41.50C)
(Moszczynska and Yamamoto 2011). These higher body temperatures as compared to
our model could be another reason for the discrepancy between our results. Moreover,
we observed a positive correlation between core body temperature and the
immunoreactivity of parkin in our study, suggesting that parkin levels increased with
rising body temperature. It is possible that parkin is involved in thermoregulation and
thereby acting as a protective agent against psychostimulant drugs (Takamatsu,
Shiotsuki et al. 2011). Also, we found a significant increase in total and membrane
synaptosomal fractions from cerebellum in our study. This finding also suggests that
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there might be an adaptational increase in parkin levels as a result of the mild oxidative
stress from our METH regimen of 4x8 mg/kg. Although no study directly shows effect of
hyperthermia on parkin, indirect evidence and our correlation between parkin and body
temperatures supports the argument that hyperthermia could play a role in regulation
of parkin levels and explain our finding.
(2)

Loading control: Loading controls are used to normalize protein bands

from electrophoresis considering their high abundance and lack of change in their levels
regardless of drug treatment. Moszczynska and colleagues observed about 40%
decrease in the levels of parkin in total synaptosomes at 1 h. Their study used alphatubulin as the loading control (Moszczynska and Yamamoto 2011). In order to validate
different loading controls, we assessed levels of two loading controls: actin and alphatubulin after binge METH. As observed from our results, METH causes a trend for an
increase in the levels of alpha-tubulin in total synaptosomes 1 h after the last dose of
METH. This suggests that METH causes change in alpha-tubulin levels and since
Moszczynska and colleagues used alpha-tubulin as a loading control, they could have
detected an exaggerated deficit in parkin than the actual effect. They compared the
levels of alpha-tubulin in total striatal synaptosomal fraction between saline- and binge
METH-treated rats and found a small and statistically non-significant increase in the
METh group (personal communication with Dr. Moszczynska). In our study, we used
Ponceau S as a loading control where no difference in staining was observed under
saline and METH treatment conditions.

81

(3)

Compensatory increase in glutathione: Endogenous antioxidants like

glutathione are known to protect the cell from oxidative stress. By conjugation with
prooxidants, glutathione prevents oxidative stress and even acts as a peroxidase. The
levels of reduced glutathione (GSH) increase in the event of any insult to the cell for
defense. However, at higher damage by METH, the levels of GSH and its related
enzymes such as glutathione peroxidase and glutathione reductase decrease
(Moszczynska, Turenne et al. 1998, Açikgöz, Gönenç et al. 2001, Pompella, Visvikisa et
al. 2003, Mirecki, Fitzmaurice et al. 2004). Cell culture studies have also shown that
METH initially increases the reduced form of glutathione followed by decrease in its
levels at higher doses of METH (Silva, Silva et al. 2013). Since we used a lower dose than
some in vivo studies (Moszczynska, Turenne et al. 1998, Açikgöz, Gönenç et al. 2001), it
is possible that the toxicity produced under our conditions is not severe enough and
leads to a compensatory increase in glutathione levels. These increased glutathione
levels would dampen the oxidative stress and lead to less damage to parkin.
(4)

Compensatory increase in parkin after oxidative stress: Dysfunction of

parkin has been observed in both Parkinson’s disease as well as METH toxicity (Leroy,
Anastasopoulos et al. 1998, Moszczynska and Yamamoto 2011). Moreover, parkin has
been found protect from oxidative stress. One study showed that dysfunction of parkin
is associated with increased oxidative stress and lipid peroxidation (Su, Duan et al.
2013). It is possible that at the toxicity produced by our dose, there is a compensatory
increase in parkin levels for neuroprotection. Mild oxidative stress is known to increase
the activity of proteasome to scavenge damaged proteins (Elkon, Melamed et al. 2004).
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Thus, it is possible that our dose released DA to a threshold which does not produce
toxicity but damages proteins to activate the UPS and thereby parkin. Another
possibility is that there is increased synthesis of parkin in the SNPc, which is axonally
transported to the terminals in the striatum upon mild oxidative stress. However, there
is no published literature supporting this. Thus, it is not unlikely that the METH-induced
toxicity in our model acts as a threshold for the adaptational increase in brain’s defense
system leading to increased parkin levels in the striatum.
(5)

Parkin monomer modified by HNE: Parkin is known to be more

susceptible to DA mediated oxidative damage than other E3 ligases (LaVoie, Cortese et
al. 2007). A number of studies have shown the covalent modification of parkin and its
aggregation by DA and its oxidation products (LaVoie and Hastings 1999, Winklhofer,
Henn et al. 2003). For example, DA quinine formation leads to oxidative damage to
parkin in rats (LaVoie, Ostaszewski et al. 2005, LaVoie, Cortese et al. 2007). Our previous
study shows that parkin is covalently modified by oxidative damage by binding of lipid
peroxidation product 4-HNE (4-hydroxynonenal). However, no aggregates of parkin
were reported in this study (Moszczynska and Yamamoto 2011). Another study has
shown that oxidative and nitrosative stress alters the solubility of parkin and destroys its
ability for neuroprotection in cell culture as well as in vivo in mice (Wang, Ko et al.
2005). This study by Wang and colleagues showed increased amounts of insoluble
parkin fractions 24-48 h after insult by an oxidative stressor. Damaged parkin monomer
can be degraded or sequestered into aggregates or both. Aggregation of parkin renders
it in a detergent-insoluble form. These oligomers of parkin are not functional
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(Winklhofer, Henn et al. 2003). As we did not observe a significant decrease in the total
levels of parkin, we expected to see an increase in the oligomeric form with
concomitant decrease in the monomeric form of parkin. However, we did not observe
any signs of increased aggregation of parkin following METH in our model. Most of the
studies on the aggregation of parkin by oxidative stress were conducted in vitro (LaVoie,
Cortese et al. 2007). The results from these studies could be different from the results
obtained from in vivo studies. We speculate that in our rats, although the parkin levels
are not altered greatly, actual damage to the protein and loss of its protective function
could have occurred by one of the above-mentioned causes. Previous study has
published about covalent modification of parkin by oxidative stress (LaVoie, Ostaszewski
et al. 2005). Similarly, it could be possible that oxidative stress causes conformational
change in the structure of parkin. To the best of our knowledge, no study has reported
such conformational change in parkin. However, if that is the case, the activity of parkin
might be affected but we will not detect a change in parkin levels due to the denaturing
conditions of our electrophoresis.
(6)

DAergic terminals form a small population in the striatum: The

nigrostriatal system comprises of innervations arising from the SNPc to the striatum.
The striatum is the main input centre for basal ganglia. It receives innervations from
multiple nerve cells (Cooper, Bloom et al. 2003). Our study focused on the DAergic
terminals in the striatum. However, the DAergic terminals form a very small population
of all the nerve terminals in the striatum. The glutamatergic terminals are present in
much higher levels than the DAergic ones. So, it is a possibility that any effect on deficit
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in parkin which is only in the DAergic terminals will be diluted by the vast majority of
parkin present in the glutamatergic and GABAergic terminals (Smith, Bevan et al. 1998,
Henny, Brown et al. 2012). Moreover, striatum also receives substantial glutamatergic
input from the subthalamic nucleus (Ribak, Vaughn et al. 1979, Yelnik 2002). Thus, it is
very difficult to estimate the change in parkin levels exclusively in the DAergic terminals.
To determine any change in parkin levels in DAergic terminals after binge METH, we
double stained synaptosomes with antibodies against parkin and DAergic marker TH. No
difference in immunoflorescence was observed between synaptosomes from saline and
METH treated rats. This might not be completely accurate since TH is also present in
noradrenergic terminals. However, noradrenergic terminals are more concentrated in
the spinal cord and olfactory bulb than striatum (Sotiriou, Vassilatis et al. 2010). So, it is
possible the results we observe are more or less representative of DAergic terminals and
that METH has no effect on the levels of parkin in DAergic nerve terminals. Also, as a
negative control for DAergic innervation, we assessed parkin levels in total and
membrane fractions of synaptosomes from cerebellum. To our surprise, we found that
METH caused an increase in the levels of parkin in both these fractions from cerebellum.
This suggests that in nerve terminals other than the DAergic population, parkin
increases following insult by METH. This increase could be a compensatory mechanism
to protect that brain region from the toxic effects of METH.
(7)

No degradation by 20S or 26S proteasome: Binge METH (4x10 mg/kg) has

been found to reduce the activity of the UPS in a dose and time dependent manner
(Moszczynska and Yamamoto 2011). Thus, if the activity of UPS is impaired, the

85

degradation of parkin decreases. The same study has also shown that binge METH
(4x10mg/kg) decreases the activity of the 26S proteasome which is responsible for
ubiqutin-mediated degradation of proteins. On the other hand, the activity of 20S
increases following oxidative stress (Grune, Reinheckel et al. 1997, Kurepa, Toh-E et al.
2008). Since parkin turnover is mediated by ubiquitination and the activity of 26S
decreases after METH, it can be envisioned that damaged parkin is not effectively
scavenged and so we do not see a decrease in the total levels of parkin. However, this
possibility is unlikely, as we do not observe parkin aggregates. It is possible that 20S
proteasome, which degrades oxidized proteins (Hershko A 1998, Davies 2001), takes
over 26S function. On the other hand, the previous study reported deficit in parkin along
with an increase in the 20S after binge METH (Moszczynska and Yamamoto 2011).
(8)

Another less likely reason for the lack of deficit in parkin observed in our

study, which is in contrast to the study of Moszczynska and Yamamoto, could be genetic
differences between outbred rats used in our study vs. rats used in their study (Phillips,
Kamens et al. 2008).
At 24 h time point, no change in parkin after binge METH was observed. First reason for
not seeing any effect at 24 h could be the dose. Since we do not see a significant deficit in
parkin at 1 h at our dose, it is possible that, by 24 h, parkin returned to the control levels by de
novo synthesis. Another explanation could be that the deficit in parkin occurred between 1 h
and 24 h and was confined to DAergic terminals. Also, due to higher number of rats in our study
(n=11) as compared to Moszczynska and Yamamoto study (n=5-7), we saw emerging
subpopulations of rats that differently respond to binge METH. Thus, a deficit in parkin due to
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damage by oxidative stress could be masked by the compensatory synthesis. METH is also
known to affect microtubules but not many studies have focused on the effect of METH on
axonal transport (Maeno, Iwasaa et al. 2000). Since parkin is neuroprotective, a theoretically
explanation could be that there is a compensatory increase in its local synthesis or its
anterograde transport from the cell bodies in the SNPc. However, no literature supporting this
has been published. It is possible is that even though the levels are not affected by METH, its
activity as an E3 ligase might be disrupted, leading to dysfunction of the UPS and subsequent
neurotoxicity.
In summary, based on literature and our findings, the discrepancy in our results and
those from the previous study can be attributed mostly to the lower dose of METH employed in
our study and the relatively lower hyperthermia observed in our rats. Consequently, the
oxidative stress and hyperthermia were not very severe in our model and so could have failed
to cause damage to parkin and the protein synthesis machinery. This might have led to the
lower damage to parkin, which could have been balanced by the increased protein synthesis as
a compensatory mechanism. Since adaptation to the insult by METH can differ between
animals, we see two subpopulations of rats where some rats show higher damage due to lower
compensatory increase of parkin in response to METH.

4.5 Parkin overexpression in the striatum:
As described previously, METH causes impaired trafficking of VMAT2 and its
mobilization to a non-synaptosomal compartment. This decrease in the levels of cytosolic
VMAT2 has been found at both 1 h and 24 h after binge regimen of METH (Riddle, Topham et
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al. 2002, Ugarte, Rau et al. 2003, Eyerman and Yamamoto 2005). Also, METH has been found to
decrease the vesicular uptake capacity and substrate binding of VMAT2 at 1 h time point
(Brown, Hanson et al. 2000). VMAT2 plays a very important role of sequestering cytosolic DA
into synaptic vesicles. In absence of such sequestration, free DA undergoes auto-oxidation and
causes neurodegeneration via oxidative stress (Miyazaki and Asanuma 2008, Guillot and Miller
2009).
Parkin is an E3 ligase in the UPS (Shimura, Hattori et al. 2000). Parkin plays a protective
role by regulating the turnover of its substrates as accumulation of many of parkin substrates
such as CDCrel-1, alpha-synuclein and Pael-R is known to cause selective degeneration of
DAergic neurons (Dong, Ferger et al. 2003, Feany and Pallanck 2003, Perren, Toelen et al. 2014).
Moreover, overexpression of parkin has been shown to protect against METH induced
neurotoxicity as assessed by reduction in depletion of TH after METH; about 50% of DAergic
axons destined for damage were protected in the striatum by parkin overexpression. The same
study also determined that this protection by parkin is not mediated by thermoregulation or
increased 20S activity (Liu, Traini et al. 2013). Thus, although the protective nature of parkin in
METH neurotoxicity has been established, the mechanism of protection remains to be
determined.

4.5.1 Validation of parkin overexpression and METH effect on parkin levels:
We used the AAV2/6 gene transfer vector to overexpress parkin in rat nigrostriatal DA
system. The AAV2/6 vector has been shown to effectively overexpress proteins in previous
studies (Dong, Ferger et al. 2003, Liu, Traini et al. 2013). Previous study by Liu and colleagues
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observed an eight fold increase in expression of parkin in rat striatum using the AAV2/6 parkincoding vector. To assess parkin overexpression in our study, we measured the levels of parkin in
total synaptosomes by western blotting. We found a five-fold increase in the levels of parkin.
This could be due to the new formulation of the AAV vector. In this experiment, binge METH
decreased parkin levels in all groups: by 23%, 30% and 35% in WT, non-coding vectormicroinjected and and parkin overexpressing rats as compared to saline counterparts. Only the
35% deficit was statistically significant; nevertheless this finding is consistent with the previous
study that showed a decrease in the levels of parkin (-48%) in striatal synaptosomes at 1 h
following binge METH (4x10 mg/kg) (Moszczynska and Yamamoto 2011) and confirms dosedependent effect of binge METH on parkin levels. No change was observed in parkin levels
between WT rats and rats injected with non-coding vector, which suggests that the vector
alone was non-toxic and did not affect the levels of parkin. Thus any increase observed in the
expression of parkin was due to the parkin-encoding vector.

4.5.2 Parkin overexpression on CDCrel-1 levels:
Once the overexpression of parkin was established, we next assessed the levels of
CDCrel-1 in total and membrane fractions of striatal synaptosomes. CDCrel-1 was shown to be a
substrate of parkin in vitro (Zhang, J Gao et al. 2000). Consistent with this study, we observed a
coimmunoprecipitation between parkin and CDCrel-1 in our in vivo study, along with a trend for
correlation between the levels of the two proteins, in WT saline-treated rats. This led us to
believe that CDCrel-1 could be a substrate of parkin in our in vivo model. However, we
observed no change in the levels of CDCrel-1 in rats overexpressing parkin, which suggested
that CDCrel-1 might not be a substrate of parkin, or is a substrate for multiple E2 ligases, in vivo.
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Our results from WT rats revealed a decrease in coimmunoprecipitation of parkin and CDCrel-1
after METH, supporting the idea that parkin is, in part, involved in regulation of CDCrel-1 levels.
In vivo conditions are different and E3 ligase-substrate dynamics are much more complex in
animals as compared to cell culture. Moreover, coimmunoprecipitation study is not an accurate
measure to determine whether CDCrel-1 is a substrate of parkin. Coimmunoprecipitation
indicates that the two proteins interact directly or in a protein complex. To establish substrate
specificity, ubiquitination assay in presence and absence of parkin would be a better measure.
To date, majority of studies on parkin and CDCrel-1 protein-protein interaction has been
conducted in vitro (Beites, Xie et al. 1999, Zhang, J Gao et al. 2000). Thus, one explanation for
lack of change in CDCrel-1 levels in parkin overexpressing rats could be that it is not a substrate
of parkin in vivo. On the other hand, parkin was overexpressed only in the nigrostriatal DA
system, not in the whole striatum. Therefore, it is possible that CDCrel-1 levels changed in
DAergic terminals upon overexpression of parkin but the change was not detected due to the
fact that DAergic terminals constitute only a small percentage of total synaptosomal population
in the striatum. Against this hypothesis is a finding from a study on parkin knock out mice that
showed unaffected levels of CDCrel-1 (Goldberg, Fleming et al. 2003). This lack of expected
increase in CDCrel-1 due to absence of parkin indicates that even though parkin might regulate
the levels of CDCrel-1, parkin is not exclusive in that function in vivo. These results support our
findings from parkin overexpression study that change in the expression of parkin does not
cause changes in the levels of CDCrel-1.

4.5.3 Parkin overexpression on trafficking of VMAT2:
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Parkin has been shown to be neuroprotective against METH toxicity. Various studies
have shown neuroprotection by overexpression of parkin suggested different mechanisms
responsible for its protective action (Bian, Liu et al. 2012, Liu, Traini et al. 2013, Rana, Rera et al.
2013). The objective of our study was to evaluate whether parkin plays a protective role by
redistribution of VMAT2 from membrane to cytoplasm after METH. The impaired trafficking of
VMAT2 after METH has been well established. A number of studies have shown a decrease in
VMAT2 in the cytoplasmic fraction of striatal synaptosomes 1 h following METH (Riddle,
Topham et al. 2002, Ugarte, Rau et al. 2003, Eyerman and Yamamoto 2007). We obtained
inconsistent results. In the first experiment, a decrease in synaptosomal cytosolic VMAT2 at 1 h
time point was not observed. In the second experiments, we observed such decrease in WT but
not in microinjected rats. No previous study has looked at the trafficking of VMAT2 after
overexpression of parkin. We expected a redistribution of VMAT2 from the plasma membrane
to the cytosol as a result of parkin overexpression. This hypothesis was based on the
assumption that increased parkin would lead to more degradation of CDCrel-1, the protein we
thought to be responsible for entrapment of VMAT2 at the membrane. The results that we
observed were contrary to our hypothesis. We did not observe any redistribution of VMAT2 or
a change in its levels in total, membrane or cytosolic fractions upon overexpression of parkin.
The possible reason for this could be that parkin expression does not affect the levels of CDCrel1 and so the VMAT2 remains trapped at the membrane. Previous study on parkin-CDCrel-1
interaction by Zhang and colleagues was in vitro which might not hold true for in vivo studies.
Also, one study has shown no change in levels of CDCrel-1 in parkin-null mice indicating low
regulation of parkin of CDCrel-1 levels (Zhang, J Gao et al. 2000, Goldberg, Fleming et al. 2003).
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According to our hypothesis, the protective role of parkin is mediated by down-regulation of
CDCrel-1. Since no change was observed in the levels of CDCrel-1 in parkin overexpressing rats,
it might explain, at least in part, why we did not see any improvement in the trafficking of
VMAT2. Alternatively, VMAT2 trafficking is impaired/changed due to a reason other than
“physical” entrapment at the membrane by CDCrel-1. Furthermore, VMAT2 trafficking might
not depend on parkin at all. In support of this conclusion, control striata overexpressing parkin
did not statistically differ with respect to VMAT2 levels in synaptosomal fraction from control
striata.

4.6 CDCrel-1 in METH toxicity:
The septin CDCrel-1 has been widely implicated in the neurodegeneration of DAergic
neurons. Under basal conditions the levels of CDCrel-1 are maintained low in the striatum as
compared to other brain regions. Overexpression of CDCrel-1 in rat brain leads to selective
DAergic cell degeneration in the SNPc (Dong, Ferger et al. 2003). Due to its selectivity for
damage to the DAergic system, we hypothesized its involvement in METH toxicity. We expected
that the tendency for a decrease in parkin would lead to a lack of effective turnover and
accumulation of CDCrel-1 in the striatum. We observed a trend for an increase in the levels of
CDCrel-1 in total synaptosomes at 1 h after the last dose of METH and only in a subpopulation
of rats. The moderate increase in CDCrel-1 in total synaptosomes at 1 h was not observed at 24
h and the levels of CDCrel-1 returned to normal. Moreover, in our second experiment (parkin
overexpression), CDCrel-1 levels did not increase after binge METH either in total or membrane
fraction at 1 h, despite the more pronounced parkin deficits. As discussed for parkin, the 8
mg/kg dose of METH used in our study could lose its effect by 24 h and so not much toxicity
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was observed at 24 h time point. Our data suggest that binge METH administration does not
lead to an increase in CDCrel-1 levels in DAergic terminals unless an increase was selective to
these terminals or CDCrel-1 was not detected by our antibody due to its aggregation or posttranslational modification (Garcia, Rodrigues et al. 2008, Herna´ndez-Rodrı´guez and Momany
2012). Assessment of CDCrel-1 levels from total and membrane synaptosomal fractions from
cerebellum showed no change in its levels in any of the rats. This suggests that there are
regional differences in the effect of METH on CDCrel-1 levels and confirms a dependence of
CDCrel-1 toxicity on DA (Dong, Ferger et al. 2003).
Our data indicate that CDCrel-1 is regulated by an E3 ligase other than parkin in rat
brain. Parkin is not the only E3 ligase present in neurons. About 616 E3 ligases with RING finger
domain are known to be present in humans (Deshaies and Joazeiro 2009). So, if parkin has been
damaged by METH then it is possible that some other E3 ligase takes over the degradation of
CDCrel-1. Several other RING finger domain E3 ligases such as Siah-1 and Siah-2 are known to
share substrates with parkin (Zhang, J Gao et al. 2000, Qi, Kim et al. 2013). Interestingly, we
observed a correlation between parkin levels and CDCrel-1 levels in saline but not METHtreated rats. We observed an interaction of parkin with CDCrel-1 in control rats and a decrease
in the interaction after METH treatment also by a second method, a coimmunoprecipitation.
These results suggest that parkin, at least in part, regulates CDCrel-1 levels in the absence of
METH, CDCrel-1 levels might be regulated, in part, by METH-induced hyperthermia.
Coexpression of heat shock protein 70 (HSP70) provided about 20% protection against
neurodegeneration caused by CDCrel-1 overexpression in rats as observed by loss of THpositive terminals in striatal sections (Jung, Fitzsimons et al. 2008). This fact is relevant as the
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HSP proteins are upregulated with stress such as increase in body temperature. Since METH
induced hyperthermia, which acts as a stress, it might cause increase in the HSPs. These
increased HSPs could be responsible for regulating the levels of CDCrel-1. Thus, the lack of
increase in CDCrel-1 after treatment with METH could be due to the protective effects of HSPs
elevated in response to METH induced hyperthermia. Against this possibility, we did not detect
correlation between CDcrel-1 immunoreactivity and core body temperatures.

4.7 VMAT2 CDCrel-1 interaction:
Impaired trafficking of VMAT2 following high-dose METH has been established. METH is
known to cause redistribution of VMAT2 from cytosol to a fraction not retained in the
synaptosomes (Riddle, Topham et al. 2002, Ugarte, Rau et al. 2003). Also, D2 agonist has been
shown to mobilize VMAT2 from membrane to cytosol, shortly after its administration (Truong,
Newman et al. 2004). Since METH causes release of DA from the terminals, it acts as an indirect
D2 agonist (Kahlig, Binda et al. 2005). CDCrel-1 is a septin with an intricate role in exocytosis.
Moreover, electron microscopy study has revealed that vesicles are linked to each other as well
as the plasma membrane through filamentous structures. Since septins are filamentous in
nature, they could be responsible for hindering the movement and recycling of vesicles to and
from the membrane (Hirokawa, Sobue et al. 1989). We hypothesized an entrapment of VMAT2associated vesicles by CDCrel-1 at the membrane. We observed coimmunoprecipitation
between VMAT2 and CDCrel-1 in both METH- as well as saline-treated rats. One out of 3 rats
showed increased interaction between the two proteins after METH. On assessment by mass
spectrometry, we observed similar results with one out of 3 rats showing much higher
interaction of CDCrel-1 with VMAT2 after METH. Our results suggest that METH might not play
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a role in the interaction between VMAT2 and CDCrel-1. But since we see two subpopulations of
rats, one of which shows increased CDCrel-1 levels, CDCrel-1 could be at least partly responsible
in holding VMAT2 at the membrane. Moreover, regression analysis of CDCrel-1 and VMAT2
levels in METH-treated rats showed correlation between the two proteins in 3 rats, which had
higher CDCrel-1 levels than the other rats. This result is consistent with a previous study which
showed decrease in exocytosis and secretion of growth hormone from cells at higher
concentration of CDCrel-1 (Beites, Xie et al. 1999). Similar to the results for CDCrel-1, we did not
observe a correlation between VMAT2 levels and METH-induced hyperthermia. Since no
correlation of hyperthermia was seen with any of the two proteins, we concluded that
hyperthermia might not play a role in the interaction between CDCrel-1 and VMAT2. Based on
the above results and existing literature, it is likely CDCrel-1 entraps VMAT2 only if the levels of
CDCrel-1 are above a certain threshold; and that even without direct interaction with VMAT2,
CDCrel-1 could be responsible for trapping it at the membrane through its filamentous network.
Alternatively, VMAT2 vesicles are entrapped at the membrane via other filamentous protein,
e.g. actin or fodrin (Hirokawa, Sobue et al. 1989).

4.8 Dopamine (DA) Content:
Using HPLC, we assessed DA levels in the membrane fraction of the synaptosomes. We
observed DA depletion at the membrane of the nerve terminal at 1 h (-30%) and more
depletion at 24 h (-45%) after the last dose of binge METH. METH releases DA from VMAT2
storage vesicles into the cytoplasm. Subsequently, DA is released to the synaptic cleft via
reverse DAT transport (Sulzer, Chen et al. 1995). The released DA is metabolized which results
in decreased total tissue levels of the neurotransmitter. It has been determined that at 1 h after

95

high-dose binge METH, the total levels of DA drop by 81% (Eyerman and Yamamoto 2005). We
found a lower deficit in DA levels at 1 h (30%). This lower depletion of DA in our study can be
attributed to a few causes. Firstly, our study used a binge regimen of 4x8 mg/kg as compared to
the Eyerman and Yamamoto study, which used a dose of 4x10 mg/kg. As discussed earlier,
higher dose of METH produces higher toxicity. Another reason for small DA depletion in our
study could be that we measured DA content in the membrane fraction of synaptosomes. The
previous study assessed total DA content. Thus, their results represent overall depletion of DA
whereas our study represents depletion of DA at the membrane of the nerve terminal.
At 24 h after binge METH (3x10 mg/kg), a ~45% decrease in striatal DA levels was found
in a previous study (Graham, Noailles et al. 2008). The DA depletion observed in our study was
similar to this result as we also observed a ~45% decrease in DA content. Our dosing regimen
(4x8 mg/kg) was different than theirs (3x10 mg/kg) but the cumulative METH dose was very
similar. Interestingly, the previous study measured DA content in striatal homogenate, whereas
we measured DA content in synaptosomal membrane fraction. Possibly, METH depletes the
vesicles in the cytosol to the same extent as vesicles at the membrane. Despite the depletion
of DA, there was no concurrent decrease in the levels of VMAT2 at the membrane at both time
points. One reason for this could be that the VMAT2 vesicles that are entrapped at the
membrane by CDCrel-1 or other fibrous protein lose their ability to sequester DA. The readily
releasable pool of vesicles sits very close to the membrane and sequester DA from there
(Sudhof 2004). Although no studies have shown entrapment of VMAT2 at the membrane
leading to loss of function, one study showed that septins could restrict the movement of
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vesicles at the membrane by forming filamentous network around them (Hirokawa, Sobue et al.
1989).

4.9 Future Directions
Our results suggest that, in rat striatum, parkin does not play a role in regulation of
VMAT2 trafficking or regulation of CDCrel-1 levels in rat striatum and that CDCrel-1 is not
responsible for lack of VMAT2 recycling to the cytosol after METH-mediated activation of DA
autoreceptors. The major limitation of our model was a very modest parkin deficit. In addition,
the number of rats per group in the parkin overexpression study was small; therefore, it is
difficult to definitively conclude that parkin does not play a role in regulation of VMAT2. These
limitations rendered our main scientific question – does parkin protects against METH
neurotoxicity via regulation of VMAT2 vesicle trafficking - not definitely answered. Future
experiments should include repetition of the study using doses of binge METH that produce
significant parkin deficit and larger sample sizes. It would be also beneficial to isolate DAergic
synaptosomes from other synaptosomal populations. Unfortunately, the techniques available
today have serious limitations. Subsequent experiments should determine what mechanism is
responsible for altered trafficking of VMAT2-bearing storage vesicles and whether VMAT2
vesicles “entrapped” at the membrane have lowered capacity to uptake DA than the vesicles in
the cytosol.
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ABSTRACT
THE ROLE OF E3 LIGASE PARKIN IN TRAFFICKING OF MONOAMINE STORAGE VESICLES IN RAT
MODEL OF METHAMPHETAMINE NEUROTOXICITY
by
Heli Chauhan
May 2015
Advisor: Dr. Anna Moszczynska
Major: Pharmacology and Toxicology
Degree: Master of Science

Methamphetamine (METH), a psychostimulant, is a widely used drug of abuse. METH is
toxic to dopaminergic (DAergic) and serotonergic (5-HT) nerve terminals in the striatum when
administered at high doses. METH releases Dopamine (DA) from vesicular monoamine
transporter 2 (VMAT2) containing synaptic vesicles and induces oxidative stress by autooxidation of DA. The VMAT2 plays a neurprotective role by sequestering cytoplasmic DA into
vesicles for storage and protection from auto-oxidation. It has previously been shown that
METH toxicity is associated with impaired VMAT2 trafficking and oxidative damage to the E3
ligase parkin. CDCrel1, a protein found to inhibit exocytosis, is regulated by parkin. We
hypothesized that METH-mediated decrease in parkin causes accumulation of the parkin
substrate CDCrel1, which entraps VMAT2 vesicles at the plasma membrane, preventing their
recycling to the cytosol. We observed inability of the VMAT2 vesicles to mobilize to the cytosol
due to a possible CDCrel-1 mediated entrapment following METH. Our findings suggest that
CDCrel1 could partially entrap VMAT2 vesicles at the membrane, impairing their normal
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recycling to the cytosol. We executed a parkin overexpression study to evaluate whether parkin
protects against the METH-induced dysfunction of VMAT2 trafficking. We found that parkin
does not reverse the impaired trafficking of VMAT2 caused by binge METH.

Keywords: Methamphetamine, parkin, VMAT2, CDCrel-1
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